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ABSTRACT  
Recent evidence has revealed that 
heterotrimeric G proteins can be activated by 
cytoplasmic proteins that share an 
evolutionarily conserved sequence called the 
Gα-binding-and-activating (GBA) motif. This 
mechanism alternative to canonical activation 
by GPCRs plays important roles in cell 
function and its dysregulation is linked to 
disease such as cancer. Here we describe a 
discovery pipeline that uses biochemical and 
genetic approaches to validate GBA candidates 
identified by sequence similarity. First, putative 
GBA motifs discovered in bioinformatics 
searches were synthesized on peptide arrays 
and probed in batch for Gαi3 binding. Then, 
cDNAs encoding proteins with Gαi3-binding 
sequences were expressed in a genetically-
modified yeast strain that reports mammalian 
G protein activity in the absence of GPCRs. 
The resulting GBA motif candidates were 
characterized by comparison of their 
biochemical, structural, and signaling 
properties with those of all previously described 
GBA motifs in mammals (GIV/Girdin, DAPLE, 
Calnuc, and NUCB2). We found that the 
phospholipase C δ4 (PLCδ4) GBA motif binds 
G proteins with high affinity, has guanine-
nucleotide exchange factor activity in vitro, and 
activates G-protein signaling in cells, as 
indicated by bioluminescence resonance energy 
transfer (BRET)-based biosensors of G-protein 
activity. Interestingly, the PLCδ4 isoform b, 
which lacks the domains required for PLC 
activity, bound and activated G proteins more 
efficiently than the full-length isoform a, 
suggesting that PLCδ4b functions as a G-
protein regulator rather than as a PLC. In 
summary, we have identified PLCδ4 as a non-
receptor activator of G proteins, and 
established an experimental pipeline to discover 
and characterize GBA motif-containing 
proteins.  
Heterotrimeric G proteins are gatekeepers 
of signal transduction that regulate fundamental 
aspects of cell biology across the full spectrum of 
the eukaryota domain, from unicellular fungi to 
multicellular mammals (1,2). They work as 
molecular switches that are turned on or off 
depending on their guanine nucleotide binding 
status. Thus, the biological activity of 
heterotrimeric G proteins is determined by their 
nucleotide handling properties (such as GDP/GTP 
exchange and GTP hydrolysis), which control the 
amplitude and duration of downstream signaling. 
At the same time, nucleotide binding and 
hydrolytic activity is modulated by a large 
network of regulators (2). The best characterized 
components of this network are membrane 
receptors of the GPCR1 superfamily. In the 
canonical paradigm, ligand-activated GPCRs act 
as Guanine-nucleotide Exchange Factors (GEFs) 
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that promote the exchange of GDP for GTP in the 
Gα subunit of a resting Gαβγ heterotrimer. As a 
consequence of GTP binding, Gα and Gβγ 
dissociate from each other and subsequently 
activate downstream effectors that propagate 
signaling intracellularly. In turn, signaling is 
terminated upon hydrolysis of GTP by Gα, which 
returns it to the GDP-bound form that reassociates 
with Gβγ. These series of reactions constitute the 
so-called canonical G protein cycle (1).  
In addition to the components described 
above as core elements of the canonical regulatory 
cycle, G proteins interact with a wide range of 
“accessory proteins” (3). These are cytoplasmic 
factors that can be classified based on their 
biochemical activity towards G proteins. The best 
characterized of these accessory proteins are 
members of the Regulators of G protein Signaling 
(RGS) family, which bind to active G proteins and 
have GTPase Activating Protein (GAP) activity 
(4,5), thereby facilitating the termination of G 
protein signaling via acceleration of GTP 
hydrolysis. This family of proteins shares a 
signature domain of ~120 aa called the RGS box, 
which confers the GAP activity (6-9). Another 
well characterized family of accessory proteins is 
defined by a signature sequence of 30-40 aa called 
the GoLoco motif, which confers Guanine 
nucleotide Dissociation Inhibitor (GDI) activity 
(10-12). Members of this family also bind to Gα 
subunits, but do so when they are in the inactive, 
GDP-bound form to prevent nucleotide exchange 
and subsequent activation (13-15). Both RGS and 
GoLoco proteins have been shown to play crucial 
roles in cell biology and human disease (12,16,17).  
 A third group of accessory proteins can be 
broadly defined based on their biochemical 
activity as GEFs. These are cytoplasmic factors 
that mimic the action of GPCRs, i.e., they promote 
the exchange of GDP for GTP on Gα subunits. 
However, in contrast to RGS and GoLoco 
proteins, the initial discovery of non-receptor 
GEFs was not accompanied by the identification 
of a shared domain or motif responsible for the 
biochemical activity, as this group was constituted 
by unrelated proteins and the domains responsible 
for the G protein regulatory activity were not 
mapped (18-22). The exception to this was GIV 
(also known as Girdin), for which a short sequence 
of ~30 aa named the Gα-Binding-and-Activating 
(GBA) motif was identified (23,24). Subsequently, 
it has been shown that the GBA motif is present in 
evolutionarily unrelated proteins and defines a 
mechanism of G protein activation by non-
receptor proteins already existing in invertebrates 
(25-27). Thus, the GBA motif represents the 
defining structural element for a subfamily of non-
receptor G protein activators with GEF activity 
(28). In mammals, this group currently consists of 
four proteins (GIV, DAPLE, Calnuc and NUCB2), 
which bind and activate Gα subunits of the Gi 
subfamily (i.e., Gαi1, Gαi2 and Gαi3). The 
structural basis for the binding and activation of 
Gαi proteins by the GBA motif in vitro has been 
studied in detail (29-31), and it has also been 
shown that the GBA motif activates G proteins in 
cells using approaches that monitor the formation 
of Gαi-GTP (cAMP or conformation-specific 
antibodies) or free Gβγ (live-cell biosensors or 
PI3K-Akt signaling) (23,26,32-36). Such signaling 
mechanisms have a profound impact on cellular 
processes such as cell migration, mitosis, polarity 
or autophagy (24,26,37-39), which underlie the 
linkage between GBA protein dysregulation and 
human disorders such as cancer, hepatic fibrosis, 
renal dysfunction, insulin resistance or pathologic 
vascularization (24,40) .  
 Despite these advances in characterizing 
the structural basis, cell signaling and disease 
linkage properties of GBA proteins, a fundamental 
question that remains unanswered is how prevalent 
this mechanism of G protein regulation is. For this, 
a critical first step is to identify which proteins, 
and how many, contain a functional GBA motif. In 
this regard, the amino acid sequence of the GBA 
motif of proteins identified to date is known, but 
this information is insufficient to systematically 
identify other GBA motifs based solely on 
sequence similarity. Although sequence similarity 
has been successfully used to identify members of 
other families of G protein regulators (e.g., RGS 
GAPs), the short length of the GBA motif and the 
limited number of validated GBA sequences limits 
the power of bioinformatics searches. For these 
reasons, bioinformatics searches for GBA motifs 
yield a large number of false positives. To 
overcome this limitation, here we describe a 
pipeline of biochemical and genetic assays that 
can be used to validate and characterize GBA 
candidates identified by sequence similarity to 
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currently known GBA proteins. Using peptide 
arrays, functional assays in genetically-engineered 
yeast and other biochemical assays, we identify 
PLCδ4 as a novel GBA motif-containing non-
receptor GEF and subsequently characterize its 
signaling properties by systematic comparison 
with all the other GBA motifs described to date.   
RESULTS  
Identification of putative GBA motifs by 
bioinformatics and peptide arrays- We envisioned 
a screening strategy to discover GBA motif-
containing G protein activators (Fig. 1A, B). We 
started by using bioinformatics to identify putative 
GBA motifs by sequence similarity, followed by a 
high-throughput peptide array assay to identify 
Gαi3 binders as initial hits. The subsequent 
validation pipeline involved genetic assays in 
yeast and further biochemical characterization. 
The underlying logic of this approach is that 
previous evidence indicates that Gαi3 binding is 
an absolute requirement for GBA-mediated G 
protein activation, and that the extent of binding 
and GEF activity correlate tightly 
(23,25,26,29,31). For this, we used the consensus 
sequence of the 7 amino acids of the highly 
conserved core of the GBA motifs identified to 
date (23,25,36,41-43) to search for similar 
sequences using ScanSite3 (44). This program 
uses a Position Specific Scoring Matrix (PSSM), 
which in our case was defined as [VLIM]-[T]- 
[VLIM]-x-[DE]-F-[VLIM] based on the consensus 
GBA motif ψ-T-ψ-x-D/E-F-ψ, where ψ is an 
aliphatic residue and x is any residue (Fig. 1A). 
Approximately 200 hits were obtained using this 
PSSM to search the human proteome based on the 
most stringent cut-off setting of ScanSite3 (0.2 
score). Proteins that were annotated in UniProt 
(45) as secreted/ extracellular or as transmembrane 
proteins in which the predicted GBA sequence 
was either in the membrane spanning region or not 
facing the cytosol were eliminated. The 88 
candidate GBA motifs that resulted from this 
curation were synthesized as 25mer peptides (in 
which the invariable F of the GBA motif occupied 
the center position) immobilized on cellulose and 
probed in batch with purified His-Gαi3 (Fig. 1C). 
This set of peptides included sequences derived 
from DAPLE and Calnuc, two previously 
validated GBA motifs that served as internal 
controls. We found that DAPLE was the strongest 
binder in the peptide array (Fig. 1C), which is 
consistent with previous observations showing that 
DAPLE has the highest affinity for Gαi3 of all the 
GBA motifs described to date (Kd ~0.1-0.4 µM) 
(26,29). On the other hand, Calnuc binding was 
weaker (Fig. 1C), which is also consistent with the 
Kd previously reported for its interaction with 
Gαi3 (Kd ~1-4 µM) (25). We reasoned that 
peptides binding Gαi3 at least as much as the 
Calnuc GBA peptide might represent 
physiologically relevant interactors because 
Calnuc has been previously shown to interact 
directly with Gαi3 in a cellular context (25,46). 
Based on this criterion, 29 GBA candidates were 
selected for further investigation. 
  
Validation of GBA candidate hits as G protein 
activators in yeast- While binding of Gαi3 to 
immobilized GBA peptides suggests that these 
sequences are capable of G protein binding in 
isolation, this might not be the case when the 
sequence is placed in the context of a folded 
protein and/ or might be insufficient for activation 
of G protein signaling. To start validating the 
GBA candidates, we used a genetic approach with 
a previously described genetic screen approach in 
yeast (47,48) (Fig. 2A). Briefly, we expressed the 
cDNA of GBA candidates in a genetically-
engineered yeast strain that lacks GPCRs and with 
the endogenous yeast Gα protein Gpa1 replaced by 
human Gαi3. In this “humanized” yeast system, 
only an exogenous G protein activator can trigger 
a signaling pathway that is normally activated as a 
pheromone response that leads to an increase in 
transcriptional activation of the FUS1 gene (Fig. 
2A). The cDNAs of GBA candidates were cloned 
as full-length proteins based on naturally occurring 
isoforms annotated in UniProt or as truncations 
corresponding to domains known or predicted to 
fold as independent units (see details in Fig. S1). 
These constructs were expressed in the 
genetically-engineered yeast strain described 
above and G protein activation was assessed by 
the activation of a FUS1 promoter β-galactosidase 
reporter (Fig. 2B). As an internal control we used 
Ric-8A, a protein that displays GEF activity 
toward Gαi proteins in vitro (19) and that we have 
previously validated as a G protein activator in this 
yeast-based assay (27). From the 29 candidates 
identified as Gαi3 binders in the peptide array 
(Fig. 1), 8 were toxic in yeast or excluded for 
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other reasons (Fig. S1). From the remaining 21 
candidate genes expressed in yeast, PLCD4 
(which encodes for the phospholipase PLCδ4) 
stood out from the rest by inducing FUS1 
activation ~80-fold over basal levels. Another 6 
candidates (NOC2L, K1045, KCIP1, KALIRIN, 
ALKB4 and MAPK2) induced FUS1 activation of 
much lower magnitude (~3-8-fold) than PLCD4 
but still comparable to the positive control Ric-8A 
(Fig. 2B). As a secondary validation of these 
results, we measured Fus3 phosphorylation in 
lysates of the same yeast cells used in the reporter 
assay. Because Fus3 phosphorylation is an event 
upstream of FUS1 transcriptional activation in the 
signaling cascade triggered by G proteins (Fig. 
2A), we reasoned that GBA candidates leading to 
increased β-galactosidase activity should also have 
increased Fus3 phosphorylation. We found that 
this was the case except for KCIP1 (Fig. 2C), 
which failed to increase Fus3 phosphorylation 
despite leading to FUS1 activation based on β-
galactosidase activity measurements. We 
concluded that KCIP1’s effect on β-galactosidase 
activity is likely due to a G protein-independent 
mechanism, while the GBA candidates PLCD4, 
NOC2L, K1045, KALIRIN, ALKB4 and MAPK2 
might be G protein activators.  
 
Validation of GBA candidate hits as direct G 
protein binders- As an independent validation of 
GBA candidates, we also investigated if they 
bound directly to G proteins. As mentioned above, 
it has been previously shown that binding of GBA 
proteins to Gαi3 correlates tightly with their ability 
to activate G protein signaling (23,25,26,29,31), so 
we established binding as a selection criterion to 
identify bona fide GBA motif-containing G 
protein activators. For this, we cloned the exact 
same sequences of the 29 GBA candidate genes 
used for the yeast assays described above as GST-
fusions for expression in E. coli (Fig. 1B). We 
could purify 15 of them in sufficient quantity and 
quality for protein-protein binding experiments. 
This set included one protein that could not be 
tested in the yeast-based assays due to toxicity 
(ABLIM3). RCN2 and TF3B were toxic in yeast 
and could not be purified from E.coli, but 
subsequent pulldown experiments with lysates of 
mammalian cells expressing these candidates ruled 
out binding to Gαi3 (Fig. S2).    
Binding of purified His-Gαi3 to the 15 
GST-fused GBA candidates purified from E. coli 
was tested in pulldown assays using permissive 
conditions (i.e., relatively high concentrations of 
proteins) to facilitate the identification of binders. 
As a positive control, we used GST-Calnuc. As 
indicated above, Calnuc is a validated GBA 
protein that binds with relatively weak affinity 
compared to other GBA motif-containing proteins 
(25,46), so we considered positive for binding 
only those GBA candidates that displayed binding 
similar to that detected with Calnuc. Based on this 
criterion, KCIP1, KALIRIN, ALKB4 and MAPK2 
did not bind to His-Gαi3 (Fig. 3). Thus, it is likely 
that the activity of these candidates in the yeast-
based system (Fig. 2B, C) is exerted via G 
protein-independent mechanisms, and we 
excluded them from further characterization as 
possible GBA motif containing G protein 
activators. On the other hand, the other three GBA 
candidates that were active in the yeast assays 
(Fig. 2B, C), i.e., PLCD4, NOC2L and K1045, did 
bind directly to His-Gαi3 (Fig. 3).  
 
PLCD4 and NOC2L, but not K1045, activate G 
protein signaling in yeast via their GBA motif- 
Next, we investigated if the GBA motif identified 
in PLCD4, NOC2L and K1045 in our 
bioinformatics searches (Fig. 1) is responsible for 
the ability of these proteins to activate G protein 
signaling in yeast (Fig. 2). For this, we mutated 
the conserved phenylalanine (F) in the GBA motif 
(Fig. 1A) of each one of these candidates to 
alanine (A) and assessed the effect of these 
mutants on β-galactosidase FUS1 reporter activity 
and Fus3 phosphorylation in the “humanized” 
yeast strain described above (Fig. 2A). It has been 
previously shown that equivalent “FA” mutations 
in any of the previously validated GBA motif-
containing proteins (GIV, DAPLE, Calnuc, 
NUCB2, GBAS-1) abolish G protein binding and 
GEF activity almost completely (23,25-27,29). 
Consistent with these previous observations, we 
found that the FA mutants of PLCD4 and NOC2L 
failed to recapitulate the activation exerted by their 
wild-type (WT) counterparts in either β-
galactosidase FUS1 reporter activity assays (Fig. 
4A) or Fus3 phosphorylation immunoblots (Fig. 
4B). On the other hand, the equivalent mutation in 
K1045 did not have an effect in the same assays 
(Fig. 4A, B), suggesting that the GBA motif of 
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this protein is not responsible for its G protein 
regulatory activity. Taken together, these results 
indicate that PLCD4 and NOC2L activate G 
protein signaling via their GBA motifs. 
 
PLCD4 and NOC2L bind preferentially to GDP-
bound Gαi3 over the GTP-bound form- Much 
like other proteins with GEF activity, all 
previously characterized GBA proteins (GIV, 
DAPLE, Calnuc, NUCB2, GBAS-1) bind 
preferentially to GDP-bound, inactive Gαi3 over 
GTP-bound Gαi3 (23,25-27,29). Next, we 
investigated if this was the case for PLCD4 and 
NOC2L. Purified His-Gαi3 was preloaded with 
GDP, GDP/AlF4- (which mimics the GTP-bound 
transition state (49,50)) or GTPγS (which is a non-
hydrolyzable GTP analog) by incubation at 30 ºC 
for 3 hours, and used as the soluble ligand in 
pulldowns with resin-immobilized GST-PLCD4. 
We found that PLCD4 binding to Gαi3 loaded 
with either of the two GTP mimetics (GDP/AlF4- 
or GTPγS) was much weaker than to Gαi3-GDP 
(Fig. 5A), suggesting that PLCD4 has G protein 
state-dependent binding properties analogous to 
those previously described for other proteins with 
GBA motifs. The same nucleotide preincubation 
conditions of 3 hours at 30 ºC diminished the 
already weak binding of NOC2L to Gαi3-GDP to 
undetectable levels, which precluded any 
comparison with GTP mimetics. To overcome this 
limitation, we omitted the GTPγS condition and 
performed the preloading step at 4 ºC for 20-30 
minutes, which is sufficient to load the G protein 
with AlF4-. Using these modified preincubation 
conditions, we found that NOC2L binds 
preferentially to inactive (Gαi3-GDP) vs. active 
(Gαi3-GDP/AlF4-) (Fig. 5B). Interestingly, K1045 
showed the opposite pattern of binding, i.e., it 
bound preferentially to GTP mimetic-bound Gαi3 
over Gαi3-GDP (not shown), which along with the 
lack of effect of the FA mutant in G protein 
activity assays in yeast (Fig. 4) supports that this 
protein does not behave like other GBA proteins. 
Studies on the significance of the K1045-Gαi3 
interaction are being pursued out of the scope of 
this manuscript. 
 
PLCD4 GBA motif, but not NOC2L GBA motif, 
binds with high affinity to Gαi3- Next, we set out 
to characterize the binding properties of the GBA 
motifs of PLCD4 and NOC2L. We have recently 
shown that a 31mer peptide corresponding to the 
GBA motif of GIV is sufficient to recapitulate the 
high affinity binding (Kd ~0.5-0.6 µM) of the 
protein (30). Using NMR spectroscopy, we also 
found that the G protein binding contacts of a GIV 
GBA peptide are the same as for a larger 200 aa 
fragment of GIV (1660-1870) (29) that is 
necessary and sufficient to activate G proteins 
(31,42). Consistently, the NMR spectroscopy 
studies also showed that the conformational 
changes in Gαi3 associated with G protein 
activation by GIV were the same for the GBA 
peptide and the larger 200 aa construct (36). Thus, 
peptides corresponding to the GBA motif can 
recapitulate well the G protein binding properties 
of the proteins they are embedded in. In order to 
quantify the Gαi3 binding affinity of the GBA 
motifs of PLCD4 and NOC2L compared to 
previously described GBA motifs in mammalian 
proteins (GIV, DAPLE, Calnuc and NUCB2), we 
synthesized fluorescently-labeled peptides and 
used them in fluorescence polarization (FP) assays 
to calculate the Kd. Following the design of the 
GIV GBA motif peptide, we generated analogous 
31-mer peptides corresponding to the GBA motifs 
of DAPLE, Calnuc, NUCB2, PLCD4 and NOC2L 
(Fig. 6A), which would be expected to yield an 
increase in FP upon binding to Gαi3 (~40 KDa). 
Consistent with previously published data, the 
GIV GBA motif bound Gαi3 with a Kd ~0.6 µM 
(Fig. 6B). DAPLE, Calnuc and NUCB2 GBA 
motifs also bound to Gαi3 with Kd‘s of ~ 0.4 µM, 
~1 µM and ~3 µM, respectively, in this assay (Fig. 
6B), which are in agreement with the binding 
affinities of larger fragments of the corresponding 
proteins using other assays (25,26). These results 
further support that isolated GBA motifs 
recapitulate well the G protein binding properties 
of the proteins they are embedded in. As for 
PLCD4 and NOC2L, we found that the former 
binds with high affinity to Gαi3 while the latter 
does not (Fig. 6B). PLCD4 GBA motif binds Gαi3 
with a Kd ~0.25 µM (Fig. 6B), which is even 
lower than that of the GBA motif of GIV or of 
DAPLE. Since GIV and DAPLE have been shown 
to regulate G protein signaling in cells via GBA-
dependent binding (23,26,31,36,37,51), this 
suggests that the GBA motif of PLCD4 might also 
be bioactive. On the other hand, NOC2L binding 
was so weak that the FP signal did not reach 
saturation even at the highest concentration of G 
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protein tested (32 µM) (Fig. 6B), thereby 
precluding Kd calculation. We estimate that the Kd 
for the NOC2L GBA: Gαi3 interaction is at least 
one order of magnitude larger than the Kd for the 
weakest GBA motif (NUCB2). This low affinity 
of the isolated GBA peptide likely reflects the G 
protein binding properties of the NOC2L protein 
because G protein activation in yeast assays and 
direct Gαi3 binding were also weak (compared to 
PLCD4) in previous experiments using a larger 
domain of NOC2L (Fig. 2, Fig. 3). Although we 
cannot rule out that the weak affinity interaction of 
NOC2L with Gαi3 is biologically relevant, we 
focused our subsequent efforts on characterizing 
the GBA motif of PLCD4.  
 
Identification of critical residues involved in 
forming the Gαi3:PLCD4 interface- To start 
characterizing the structural properties of the 
interface formed between PLCD4 and Gαi3, we 
generated a homology-based model of the 
complex. For this, we used the previously 
described crystal structure of a GBA-like synthetic 
peptide called KB-752 bound to Gαi1 as a 
template (41). This model resolves a 13 amino 
acid stretch of PLCD4 containing the core of the 
GBA motif. As expected, this model predicts that 
the GBA motif of PLCD4 binds to Gαi3 similar to 
other GBA motifs, i.e., it docks onto the cleft 
formed by the Switch II (SwII) region and α3 helix 
of Gαi3 (Fig. 7A). Consistent with this mode of 
binding, we found that myristoylation of the N-
terminus of Gαi, which is far from the SwII/α3 
pocket in crystal structures, does not affect binding 
to the GBA motif of PLCD4 (Fig. S3). To validate 
more extensively the predicted conservation 
between the mode of binding of PLCD4 GBA 
motif and that of other GBA motifs, we tested its 
binding to a battery of 18 Gαi3 mutants previously 
used to characterize the binding of GIV and 
DAPLE GBA motifs (29). This set includes 
mutants within or near the SwII/α3 region 
previously shown to inhibit, enhance or have no 
effect on binding to the GBA motif of GIV or 
DAPLE (29). We reasoned that this systematic 
approach would allow us to define a “fingerprint” 
of PLCD4 GBA motif binding properties based on 
the effect of different mutants and that this 
fingerprint could be compared to that of 
previously characterized GBA motifs (29). For 
this, we performed FP experiments with a 
fluorescently labeled PLCD4 GBA peptide to 
quantify the Kd for each mutant and then 
calculated the fold change in affinity compared to 
Gαi3 WT (Fig. 7B). This dataset for PLCD4 GBA 
motif was compared to previously obtained data 
(29) for GIV GBA motif and DAPLE GBA motif 
using the same experimental conditions. As shown 
in the heat map and correlation plots in Fig. 7B, 
there was good agreement between the effects of 
Gαi3 mutants on the binding of PLCD4 GBA 
motif and on GIV or DAPLE GBA motif. The 
Pearson’s correlation coefficient was 0.89 for 
PLCD4/ GIV and 0.95 for PLCD4/ DAPLE. In 
general, mutants that diminished affinity for GIV 
or DAPLE also had diminished affinity for 
PLCD4, and mutants that increased affinity, like 
S252A, also did so for all the GBA motifs (Fig. 
7B). A notable exception was the effect of the 
W258F mutation. While this mutation diminishes 
the affinity for GIV (~3.5 fold) and DAPLE (~2-
fold), it increases affinity for PLCD4 (~2 fold). 
Although our homology model does not include 
the predicted contacts made by W258 with the 
GBA motif (Fig. 7A), it is reasonable to think that 
the difference in binding upon W258 mutation 
arises from the divergence of the sequence in the 
C-terminal region (i.e., downstream of the 
conserved F) of the GBA motifs of PLCD4, GIV 
and DAPLE (Fig. 6A). Overall, these results 
indicate that, barring some nuanced differences, 
the GBA motif of PLCD4 physically engages G 
proteins in a manner similar to previously 
characterized GBA motifs.  
 
Consistent with the homology model (Fig. 
7A), some of the most marked defects in GBA 
motif binding were observed upon mutation of the 
aromatic residues W211 and F215 in Gαi3 (Fig. 
7B), which are predicted to form extensive 
hydrophobic contacts with PLCD4 GBA motif. 
More specifically, residues L224, F227 and L228 
of PLCD4 are located on one side of the α-helical 
region of the GBA motif that docks onto the Gαi3 
hydrophobic groove dominated by W211 and 
F215 (Fig. 7A, right). Again, this is a feature 
conserved with previously described GBA motifs, 
as all of them have hydrophobic residues in these 
positions (Fig. 1A) and mutation of the invariable 
phenylalanine almost completely abolishes 
binding for GIV, DAPLE, Calnuc and NUCB2 
(23,25,26). When we tested if this was also the 
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case for PLCD4, we found that mutation of F227 
to alanine (“FA”) caused a marked but incomplete 
decrease in Gαi3 binding compared to PLCD4 
GBA WT (Fig. 7C). This incomplete reduction in 
binding is also in agreement with the incomplete 
ablation of activity in yeast-based assays using the 
same mutant (Fig. 4A, B). We reasoned that 
PLCD4 binding to Gαi3 might be stabilized by 
contacts established by the other conserved 
hydrophobic residues in the GBA motif (i.e., 
L224, L228), so we tested if multi-position 
mutants F227A/L228A (“FALA”) and 
L224A/F227A/L228A (“LAFALA”) were more 
efficient in disrupting the interaction. We found 
that this is the case because both FALA and 
LAFALA displayed undetectable binding to Gαi3 
(Fig. 7C). These results not only indicate that this 
GBA:G protein interface has properties slightly 
different from those described for other GBA 
motifs, as suggested by the Gαi3 mutants profiling 
results (Fig. 7A), but also identify the double 
mutant F227A/L228A as a useful tool to 
completely blunt the physical coupling of PLCD4 
GBA motif to Gαi3. 
 
PLCD4 GBA motif activates Gαi3 in vitro- 
Having identified a powerful tool to assess the 
specificity of PLCD4 GBA motif action (i.e., the 
FALA mutant), we set out to determine if this 
motif had GEF activity like previously 
characterized GBA proteins and related synthetic 
peptides (23,25-27,41,43). We have previously 
validated that steady-state GTPase assays 
accurately reflect the effect of the GBA proteins 
GIV, DAPLE, Calnuc and NUCB2 on Gαi3 
nucleotide exchange, providing results that are 
indistinguishable from those obtained from GTPγS 
binding experiments done in parallel 
(25,26,29,42). This is explained well by the much 
faster rate of GTP hydrolysis versus nucleotide 
exchange (2 orders of magnitude for Gαi) (52), 
which makes GDP/GTP exchange the rate limiting 
step under steady-state GTPase conditions. Using 
this assay, we found that increasing amounts of 
GST-fused PLCD4 GBA motif increased the rate 
of nucleotide exchange on purified His-Gαi3 more 
than 2-fold (Fig. 7D), which is comparable to 
levels previously observed for other regulators of 
the same family (23,25-27,41,43). This GEF 
activity was specific because parallel reactions 
with the G protein binding-deficient PLCD4 
FALA mutant revealed no activity (Fig. 7D). 
When analogous experiments were performed 
with Gαi3-Gβγ heterotrimers instead of with free 
Gαi3, we found that PLCD4 WT, but not the 
FALA mutant, also lead to increased G protein 
activity, although somewhat less efficiently (~1.7 
fold for the trimer vs. ~2 fold for free Gαi3) (Fig. 
7D). Similar results were obtained for His-GIV-
CT (aa 1660-1870, containing the GBA motif), in 
that it also increased activity with Gαi3-Gβγ 
heterotrimers but somewhat less efficiently than 
with free Gαi3 (~2 fold for the trimer (Fig. 7D) vs. 
~2.5-3 fold for Gαi3 (23,31,42). The lower GEF 
efficacy on heterotrimers compared to monomeric 
Gαi is consistent with previously reported 
competition between GBA motifs and Gβγ for 
binding to Gαi (23,26). These results indicate that 
the GBA motif of PLCD4 has GEF activity in 
vitro. 
 
PLCD4 GBA motif activates G protein signaling 
in mammalian cells- Next, we investigated if the 
GBA motif of PLCD4 works as an activator of G 
proteins in cells. For this, we took advantage of a 
recently developed experimental system used to 
demonstrate that membrane recruitment of GIV is 
sufficient to trigger G protein activation in cells 
(36,53). The underlying principle of this system is 
that Gαi subunits are constitutively attached to 
cellular membranes while GIV is predominantly in 
the cytosol, such that only upon recruitment of 
GIV (or its GBA motif in isolation) to membranes 
can it activate G proteins (36,53). Experimentally, 
membrane recruitment is achieved via chemically-
induced dimerization (CID) of FKBP and FRB 
domains with rapamycin (54) (Fig. 8A, left). FRB 
is fused to the first 11 aa of Lyn (Lyn11-FRB), 
which targets it to the plasma membrane (55,56), 
whereas FKBP is fused to a GBA sequence 
(FKBP-GBA) and remains in the cytosol. Thus, 
rapamycin induces the translocation of FKBP-
GBA to the plasma membrane, where Lyn11-FRB 
localizes. The effect of this translocation on G 
protein activation is monitored in real time by 
bioluminescence resonance energy transfer 
(BRET) using a genetically-encoded biosensor 
system. In this system, dissociation of Gαβγ 
heterotrimers upon activation leads to the 
association of free Venus-Gβγ (BRET acceptor) 
with the C-terminal domain of its effector GRK3 
fused to an enhanced luciferase (Nluc, BRET 
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donor), which leads to an increase in BRET 
(57,58) (Fig. 8A, right). Using this experimental 
system, the amplitude of G protein activation upon 
GIV GBA translocation is only slightly lower than 
that obtained upon activation of a Gi-coupled 
GPCR like the muscarinic M4 receptor with 
saturating concentrations of ligand (36,53). To 
assess the G protein regulatory activity of PLCD4 
and systematically compare it to other GBA 
proteins, we generated FKBP fusions of the GBA 
motifs of GIV, DAPLE, Calnuc and NUCB2 as 
well as of PLCD4 (Fig. 8B), and expressed them 
in HEK293T cells along with Lyn11-FRB and the 
components of the BRET biosensor. As in our 
previous report (36), addition of rapamycin 
induced a rapid increase in BRET in cells 
expressing FKBP-GBA GIV WT but not FKBP-
GBA GIV FA (Fig. 8C), indicating GBA-
dependent G protein activation upon membrane 
translocation. Similarly, all the other GBA motifs, 
including PLCD4, led to an increase in BRET 
upon rapamycin stimulation that was not 
recapitulated by the corresponding FA mutants 
(Fig. 8C). However, the amplitude of the BRET 
responses was different depending on the specific 
GBA motif used (Fig. 8C). In fact, the order of 
potency of the GBA motifs in this readout 
matched very well with their affinity for Gαi3 
determined by FP using the exact same 31-mer 
GBA sequences (Fig. 6A), with PLCD4 as the 
most potent activator and highest affinity binder. 
Also consistent with the relative affinity of 
different GBA motifs for Gαi3, we found that the 
corresponding GBA sequence of NOC2L only 
induced a marginal increase of BRET in this 
assay, which was almost negligible in comparison 
with PLCD4 (Fig. S4). One difference between 
the FKBP-GBA motif of PLCD4 and the other 
proteins is that the FA mutation failed to 
completely abolish the BRET response (Fig. 8C). 
This is not surprising given that this mutant still 
binds weakly to Gαi3 (Fig. 7C) and moderately 
activates G protein signaling in yeast (Fig. 4A, B). 
When PLCD4 mutants “FALA” and “LAFALA”, 
which completely disrupt Gαi3 binding and GEF 
activity in vitro (Fig. 7C, D), were compared side 
by side with FKBP-PLCD4 GBA WT and the FA 
mutant, we observed no measurable G protein 
activation upon rapamycin stimulation as 
determined by BRET (Fig. S5). These results 
confirm the specificity of the GBA-mediated 
activation of G proteins by PLCD4.  
 
 To further substantiate the conclusion that 
PLCD4 GBA activates G protein signaling in 
cells, we investigated whether it regulates a 
signaling event downstream of G protein 
activation (rather than measuring activation at the 
level of the G protein as described above). The 
canonical effectors of G proteins of the Gi family 
are adenylyl cyclases (AC), the enzymes 
responsible for the synthesis of cAMP. It is well 
established that upon Gi activation, GTP-bound 
Gαi subunits bind AC to negatively modulate its 
activity (59). We used the same rapamycin-
induced translocation system as above to trigger 
the action of FKBP-fused GBA motifs of PLCD4 
and GIV (as a control) on G proteins (Fig. 8D). 
The output detection system was a BRET-based 
biosensor (Nluc-EPAC-VV) that monitors 
intracellular cAMP levels in real time (57,60) 
(Fig. 8D). Briefly, HEK293T cells were 
stimulated with forskolin to induce the direct 
activation of AC and subsequently treated with 
rapamycin to translocate the GBA motifs to the 
plasma membrane. While rapamycin had no effect 
on the forskolin-induced cAMP levels in control 
cells not expressing any FKBP-GBA fusion, it led 
to a substantial decrease of cAMP (~25%) in cells 
expressing FKBP-GBA GIV or FKBP-GBA 
PLCD4 (Fig. 8D, E, F). The response observed for 
FKBP-GBA PLCD4 was abolished when the same 
experiment was repeated using the Gαi-bindini 
deficient FALA mutant (Fig. S6). Although the 
amplitude of the GBA motif-mediated responses 
was not as marked as the one observed upon 
maximal activation of a Gi-coupled GPCR like the 
α2A adrenergic receptor, which led to a ~40-45% 
reduction in cAMP (Fig. 8F), these findings are 
consistent with the activation of Gi-dependent 
signaling by the GBA motifs of both GIV and 
PLCD4. Taken together, these results demonstrate 
that the GBA motif of PLCD4 can activate G 
protein signaling in cells. 
 
Gαi3 binds more strongly to PLCδ4b than to 
PLCδ4a- While the results above strongly indicate 
that the GBA motif of PLCD4 leads to robust G 
protein activation, we set out to characterize if this 
was the case for the GBA motif in its native 
context of PLCD4 proteins. Based on the curated 
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annotations for human PLCD4 in UniProt, this 
gene encodes for two different isoforms of PLCδ4, 
i.e., PLCδ4a (61) and the shorter isoform PLCδ4b 
(62) (Fig. 9A). PLCδ4a is considered the 
canonical isoform of PLCδ4 and contains all of the 
domains characteristic of this family (in order 
from N to C terminus): PH domain that can bind 
phosphoinositides, EF-hands, catalytic TIM barrel 
(with X- and Y-boxes) responsible for the 
phospholipase activity, and C-terminal C2 domain 
(Fig. 9A). Interestingly, PLCδ4 contains 2 
canonical EF-hands (although EF-hands in PLCδ 
or PLCβ isoforms do not bind Ca2+ (63-65)) 
followed by an EF-hand-like domain (203-237 
amino acids) of uncharacterized function. The 
GBA motif of PLCD4 characterized in this work 
overlaps with this EF-hand-like domain, 
suggesting that G protein regulation might be its 
actual function. It is also interesting that the 
PLCδ4b isoform contains this EF-hand-like/ GBA 
sequence but is truncated before the catalytic TIM 
barrel, which makes it a protein without PLC 
activity but potentially with G protein regulatory 
activity. This idea is supported by our results in 
yeast-based experiments (Fig. 4A, B), which 
showed GBA-dependent G protein activation by a 
PLCD4 construct that closely resembles PLCδ4b 
(i.e., corresponding to amino acids 1-260) (Fig. 
9A). 
 
 The finding of a GBA sequence that 
overlaps with an EF-hand fold is not novel, as 
Calnuc and NUCB2 also share this property (25). 
Moreover, results from our bioinformatics 
searches and peptide arrays (Fig. 1) showed an 
enrichment for GBA motifs located in EF-hands, 
i.e., 10 out of the 29 GBA hits in the peptide array 
correlated with EF-hands. These findings are 
explained well by the overlap of the consensus 
GBA motif sequence ψ-T-ψ-x-D/E-F-ψ with the 
C-terminal segment of the consensus EF-hand 
sequence D-x-D-x-D-G-ψ-D/S/T-x-x-D/E-F 
(underlines indicate the overlap). However, our 
data also demonstrates that G protein binding (and 
regulation) is not a widespread function of EF-
hands because only one (i.e., PLCD4) of the 10 
candidate GBA motifs turned out to have G 
protein regulatory activity. Instead, G protein 
regulatory activity seems to correlate with atypical 
EF-hand sequences, likely without Ca2+ binding 
function, as exemplified by the EF-hand-like of 
PLCD4. Interestingly, the second EF-hand of 
Calnuc, which is the one overlapping with its 
GBA motif, is also considered a non-canonical 
EF-hand based on sequence divergence (66,67), 
and it only regulates G proteins when it is not 
bound to Ca2+ (25). 
 
 To assess protein-protein binding of 
PLCδ4 isoforms to G proteins, lysates of 
HEK293T cells expressing myc-tagged PLCδ4a 
and PLCδ4b were used in pulldown assays with 
purified GST-Gαi3. We found that PLCδ4b binds 
Gαi3 much more robustly than PLCδ4a (Fig. 9B). 
A possible explanation for this difference is that 
the GBA motif is more accessible to the G protein 
in the shorter isoform (in which it is located near 
the C-terminal end) than in the longer one (in 
which it is sandwiched between the EF-hands and 
the catalytic TIM barrel). Regardless of the 
explanation for the difference in Gαi3 binding 
among isoforms, these results suggest that PLCδ4b 
might be a better regulator of G protein signaling 
in cells than PLCδ4a.   
 
PLCδ4b but not PLCδ4a promote G protein 
activation in cells- We used the BRET-based 
biosensor that directly monitors G protein activity 
described above (i.e., V-Gβγ/ GRK3ct-Nluc) to 
assess the function of PLCδ4a and PLCδ4b in 
cells. Myc-tagged constructs were expressed in 
HEK293T cells and BRET measured under 
steady-state conditions. Consistent with the 
protein-protein binding results, we found that 
expression of PLCδ4b but not PLCδ4a led to an 
increase in G protein activity as determined by 
BRET (Fig. 9C). This BRET enhancement was 
not reproduced by the PLCδ4b FALA mutant 
(which is GEF-deficient, Fig. 7D), indicating that 
PLCδ4b activates G proteins in mammalian cells 
via its GBA motif. Equivalent results were 
obtained using a construct consisting of PLCD4 aa 
1 to 260 (Fig. S7), which is similar to PLCδ4b and 
identical to the construct used in yeast-based 
experiments (Figs. 2, 4) and in in vitro protein 
binding experiments (Fig. 3, 5). These results 
further validate that PLCD4 exhibits consistent G 
protein regulatory activity across different 
experimental systems.  
 
 To further substantiate that PLCδ4b 
activates G protein signaling in cells, we 
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investigated whether it regulates cAMP levels. For 
this, we fused full-length PLCδ4b (and PLCδ4a) to 
FKBP and tested the effect of recruiting the 
construct to the plasma membrane on forskolin-
induced cAMP levels.  We found that membrane 
recruitment of full-length PLCδ4b led to a 
decrease in cAMP levels (Fig. 10A, B), much like 
the recruitment of its GBA motif (Fig. 8E, F). 
PLCδ4b-mediated inhibition of cAMP was 
abolished upon introduction of the FALA mutation 
(Fig. S8), indicating that the observed response is 
GBA motif-dependent. The effect of full-length 
PLCδ4b was more modest than that of its GBA 
motif alone (~12% vs. ~25% [Fig. 8], 
respectively), which might be explained by their 
relative levels of expression (Fig. S8). Based on 
our results from BRET-based G protein activity 
assays in Fig. 9, we predicted that PLCδ4a would 
not inhibit forskolin-induced cAMP levels. 
Surprisingly, we found that, even though PLCδ4a 
did not inhibit cAMP, it caused an enhancement of 
forskolin-induced cAMP levels (Fig. 10A, B). We 
reasoned that this enhancement of forskolin-
induced cAMP levels was due to its catalytic PLC 
activity (which is absent in PLCδ4b). This is not 
far-fetched because several AC isoforms are 
activated by increased Ca2+ levels or Ca2+-
dependent mechanisms (59), a direct downstream 
effect of PLC activity. We found that the effect of 
PLCδ4a on cAMP was indeed dependent on its 
PLC activity, as it was inhibited by the small 
molecule PLC inhibitor U73122 (Fig. 10D). On 
the other hand, U73122 had no effect on PLCδ4b-
mediated inhibition of forskolin-induced cAMP 
levels (Fig. 10D), which is consistent with the lack 
of a catalytic PLC domain in this isoform and 
supports the specificity of the effect of the 
inhibitor on PLCδ4a. Taken together, these 
findings confirm that, instead of working as a 
phospholipase, PLCδ4b is a non-receptor activator 
of heterotrimeric G proteins that functions via a 
defined GBA motif.  
 
 
 
DISCUSSION  
The main advances reported here are three: (i) the 
validation of a pipeline to identify and validate 
novel GBA motif-containing G protein regulators, 
(ii) the discovery of PLCδ4b as a novel non-
receptor G protein activator with a GBA motif, 
and (iii) a systematic characterization of the 
biochemical, structural and signaling properties of 
all the GBA motifs described to date. Together, 
these findings advance our understanding of an 
understudied family of G protein regulators with 
important biological functions and establish a 
framework for their discovery and 
characterization.   
The existence of a specific sequence that 
defines a group of non-receptor G protein 
activators (i.e., the GBA motif) is useful but 
insufficient information to reliably identify novel 
members of this family of G protein regulators 
based solely on sequence similarity. This contrasts 
with other families of G protein regulators like 
RGS GAPs, as many RGS proteins were 
discovered based on sequence similarity. This is 
because, while the GBA motif is a short sequence 
found in only a few proteins, RGS proteins are 
defined by a longer sequence (i.e., the RGS box, 
of about 120 aa) present in a larger number of 
proteins, thereby providing a more robust training 
set for bioinformatics searches. The findings 
reported here help to overcome the shortcomings 
of sequence-based searches of GBA regulators in 
two ways. The first is that increasing the number 
of GBA sequences that bind to G proteins will be 
helpful to improve the training set for future 
bioinformatics searches. Second, and probably 
more useful, is the pipeline of high and medium 
throughput assays to filter out false positives from 
sequence searches. Dozens or hundreds of GBA 
motif candidates can be rapidly assessed for the 
essential biochemical property of binding to G 
proteins by using peptide arrays, while yeast is 
used as a secondary system of facile genetic 
manipulation to test for G protein signaling 
activity. It is tempting to speculate about the 
implementation of a similar pipeline to discover 
new members of another family of G protein 
regulators such as GDIs that contain the so-called 
GoLoco motif. Much like the GBA motif family, 
these regulators are characterized by a short 
sequence (30-40 aa) present in a relatively small 
number of proteins, and the pipeline of assays 
described here is compatible with their 
characterization.   
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Related to the above, our comprehensive 
characterization of all the GBA motifs described 
to date in mammals (GIV, DAPLE, Calnuc, 
NUCB2 and, now, PLCD4) provides informative 
benchmarks and tools to assess the biochemical, 
structural and signaling properties of this family. 
Consistent with prior data obtained through the 
characterization of GIV’s GBA motif by 
mutagenesis (23,29,31), the potency of different 
GBA motifs in triggering G protein activation in 
cells (Fig. 8) correlates with their affinity for G 
proteins in vitro (Fig. 6). Likewise, all share a 
common binding site on the G protein, although 
the newly identified GBA motif in PLCδ4 has 
slightly different requirements to establish the 
protein-protein interaction. Collectively, it appears 
that the C-terminal region of the GBA motif 
downstream of PLCδ4 F227, which diverges in 
sequence from other GBA motifs (Fig. 6A), might 
establish different protein-protein contacts, as 
indicated by the requirement of simultaneous 
mutation of F227 and L228 to alanine to 
completely disrupt binding and by the different 
impact of the Gαi3 W258F mutation on PLCδ4 
binding compared to other GBA motifs. 
Elucidating such nuanced differences in the mode 
of G protein binding by GBA motifs will require 
atomic resolution structures.    
 The new GBA motif-containing protein 
we identified here, PLCδ4, presents a number of 
interesting properties. The most striking one is that 
we have been able to validate the G protein 
regulatory activity for one of the two annotated 
isoforms, PLCδ4b. While both PLCδ4a and 
PLCδ4b have been reported to be ubiquitously 
expressed in different tissues (61,62), PLCδ4b 
appears to be a G protein regulator rather than a 
phospholipase. This is because this isoform is 
composed only of the PH domain and the EF-
hands, lacking the catalytic TIM barrel required 
for lipase activity. Interestingly, it has been 
previously reported that the PH domain of PLCδ4 
in isolation, but not the full-length protein 
corresponding to PLCδ4a, localizes to the plasma 
membrane via phosphoinositide binding— 
different manipulations that decrease PIP2 levels 
lead to the release of PLCδ4 PH domain from the 
plasma membrane into the cytosol (68). Because 
PLCδ4b consists primarily of the PH domain with 
only a C-terminal extension containing the EF-
hands, it is likely that its subcellular localization 
and regulation by phosphoinositides recapitulates 
the properties of the PH domain in isolation. This 
raises the interesting possibility that the G protein 
regulatory activity of PLCδ4b might be controlled 
by alterations in phosphoinositide levels. We have 
recently shown that the main mechanism by which 
GBA proteins regulate G protein signaling is by 
spatial proximity (36)— i.e., G protein activation 
occurs when the GBA motif is recruited to 
membranes in physical proximity to the target G 
protein, Gαi, which is constitutively membrane-
bound. Thus, if phosphoinositides regulate the 
localization of PLCδ4b at the plasma membrane, 
they might also impact its G protein regulatory 
function. At a physiological level, it is not possible 
at this time to envision what function the GBA 
motif of PLCδ4 might have. PLCδ4 function has 
not been extensively characterized, but insights 
from mice in which the PLCδ4 gene has been 
knocked out indicate that it is required for male 
fertility (69,70). However, this function is likely 
exerted by the PLCδ4a isoform and we have not 
observed G protein regulatory activity for this 
isoform. While we cannot rule out that the GBA 
motif of PLCδ4a might become functional under 
specific circumstances that would make the GBA 
motif accessible to G proteins (as PLC enzymes 
are believed to undergo significant conformational 
and/or spatial rearrangements (71,72)), the only 
available evidence for G protein regulatory 
activity is for the PLCδ4b isoform. Unfortunately, 
the function(s) of this isoform are still unknown. 
Further work will be required to elucidate the role 
of the GBA motif in the biological functions of 
PLCδ4.  
 
EXPERIMENTAL PROCEDURES 
Reagents and Antibodies- Unless 
otherwise indicated all reagents were of analytical 
grade and obtained from Fisher Scientific or 
Sigma. Cell culture media and goat anti-rabbit and 
goat anti-mouse Alexa Fluor 680 antibodies were 
from Life Technologies. Fluorescein di-β-D-
galactopyranoside was from Marker Gene 
Technologies, and the protein inhibitor mixture 
was from Sigma (catalog no. S8830). Leupeptin, 
pepstatin, and aprotinin were from Gold 
Biotechnology. All restriction endonucleases and 
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Escherichia coli strain BL21(DE3) were from 
Thermo Scientific. E. coli strain DH5α was 
purchased from New England Biolabs. Pfu ultra 
DNA polymerase was purchased from 
Agilent. Rabbit antibodies raised against Gαi3 (C-
10), and Gβ (M-14) were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Mouse 
monoclonal antibodies raised against α-tubulin 
(catalog no. T6074) and His-tag (catalog no. 
H1029) were from Sigma, and for HA tag 
(12CA5) were from Roche. Rabbit antibodies for 
ppERK (catalog no. 4370) and mouse antibodies 
for Myc (catalog no. 9B11) were from Cell 
Signaling. Rabbit polyclonal antibody for RFP 
was from Abcam (catalog no. 62341). Goat anti-
rabbit and goat anti-mouse IRDye 800 F(ab′)2 
were from Li-Cor Biosciences (Lincoln, NE). 
Bioinformatics Searches and Analyses- 
The search for proteins with a GBA motif in H. 
sapiens was performed in ScanSite 3  using the 
QuickMatrix Method (44). Briefly, we used the 
sequences of known GBA motifs of the proteins 
GIV, DAPLE, Calnuc, NUCB2, GBAS-1 and the 
synthetic peptides KB-752 and GSP (23,25-
27,41,43) to design the pattern as [VLIM]-[T]-
[VLIM]-x-[DE]-F-[VLIM] and generate the 
corresponding position-specific scoring matrix 
(PSSM) to search in the H. sapiens proteome in 
the NCBI Protein GenPept/RefSeq database.   
Synthesis of Peptide Libraries and Gαi3 
Overlay- Libraries of immobilized peptides were 
produced by automatic SPOT synthesis on 
continuous cellulose membrane supports 
(Whatman 50 cellulose membranes) using Fmoc 
(fluoren-9-ylmethoxycarbonyl) chemistry with the 
AutoSpot-Robot ASS 222 (Intavis Bioanalytical 
Instruments AG) (73). Candidate GBA motif 
peptides were synthesized as 25-mer peptides in 
which the invariable phenylalanine (F) of the core 
of the GBA motif was in the central position. 
Individual peptide-cellulose complexes were 
solubilized and re-spotted on Celluspot® slides for 
subsequent probing. Slides were primed in binding 
buffer (4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 
7.4, 137 mM NaCl, 2.7 mM KCl, 5mM MgCl2, 
1mM DTT, 30µM GDP, 1% (v:v) TX100) and 
blocked for 1 h in the same buffer supplemented 
with 5% (w:v) BSA. Slides were incubated for 2h 
at room temperature with rat His-Gαi3 at 20 µg/ 
ml (~0.5 µM) in the same buffer. After 4 washes, 
slides were sequentially incubated with primary 
(rabbit anti-Gαi3, 1: 250; 90 min) and secondary 
(goat anti-rabbit Alexa Fluor 680; 60 min) 
antibodies. As a control for non-specific detection 
of the peptide sequence by the primary and/or 
secondary antibody, a replicate peptide array slide 
was processed in parallel under identical 
conditions except that no His-Gαi3 was added. 
Images were acquired and spot intensity quantified 
in an Odyssey infrared scanner (Li-Cor). Specific 
binding was quantified by subtracting the signal 
intensity for each spot in the slide without Gαi3 
incubation from the corresponding spot signals in 
the slide with Gαi3 incubation, and normalized by 
dividing the resulting number by the intensity of 
the spot after Coomassie blue staining. Images 
were processed using the ImageJ software (NIH) 
and assembled for presentation using Photoshop 
and Illustrator (Adobe).  
Plasmid Constructs- Cloning of GBA 
candidates into plasmids for expression in yeast, 
bacteria or, in some cases, mammalian cells was 
done using a ligation independent cloning (LIC) 
system (74). Briefly, sequences corresponding to 
the GBA candidates indicated in Fig. S1 were 
amplified by PCR from plasmids obtained from 
OpenBiosystems, Addgene, GenScript or 
individual investigators. The amplified fragments 
contained extensions at the 5’ and 3’ ends that 
made them compatible with any of the following 
LIC plasmids: pLIC-YES2 (yeast, described in 
(27)), pLIC-GST (bacteria) and pLIC-myc 
(mammalian). pLIC-GST and pLIC-myc plasmids 
were kindly provided by J. Sondek (UNC-Chapel 
Hill) (75). pLIC-YES2-Ric-8A has been described 
before (27). Cloning of the pET28b-Gαi3 and 
pGEX-Gαi3 plasmids for the expression of rat 
His-Gαi3 or GST-Gαi3, respectively, in bacteria 
have been described previously (23). pET24a-
Gαi3 for the expression of human Gαi3 has been 
described in (29). The GBA motif sequences of 
human GIV (aa 1671-1701), human DAPLE (aa 
1661-1691), human Calnuc (aa 303-333), human 
NUCB2 (aa 304-334) or human PLCD4 (aa 213-
243) inserted into the NruI/BamHI sites of the 
pmRFP-FKBP-pseudojanin plasmid (Addgene 
#37999), which results in the replacement of the 
pseudojanin sequence by the GBA motifs to 
generate constructs that encode for RFP-FKBP-
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GBA fusions. Plasmids encoding the GBA motif 
of human PLCD4 (aa 213-243) or of human GIV 
(aa 1660-1701) fused to GST were generated by 
LIC using the pLIC-GST vector mentioned above. 
The pT7-5-Gαi1 plasmid (which bears an internal 
hexahistidine tag in the b/c loop of Gαi1) was 
kindly provided by H. Hamm (Vandebilt 
University) (76) and the pbb131 plasmid encoding 
N-myristoyl transferase (NMT) (77) was a gift 
from Maurine Linder (Cornell University). The 
plasmid encoding Lyn11-FRB has been described 
previously (36). pcDNA3.1-A1R, pcDNA3.1-
Venus(1-155)-Gγ2 (VN-Gγ2) and pcDNA3.1-
Venus(155-239)-Gβ1 (VC-Gβ1) were kindly 
provided by N. Lambert (Augusta University, GA) 
(58). pcDNA3.1-masGRK3ct-Nluc and 
pcDNA3.1-Nluc-EPAC-VV (57) were a gift from 
K. Martemyanov (Scripps Research Institute, FL). 
The pcDNA3-Gαi3 plasmids for the expression of 
rat Gαi3 in mammalian cells and the pET28b-GIV 
(1660-1870) plasmid for the expression of His-
GIV-CT in E. coli have been described previously 
(23,42). Plasmids for the expression of N-
terminally tagged myc-PLCδ4a, myc-PLCδ4b and 
myc-PLCδ4 (1-260) were generated by PCR 
amplification from full-length PLCD4 and 
insertion into pLIC-myc. The primers for myc-
PLCδ4b included a 3’ extension to add the amino 
acids in its C-terminus that diverge from myc-
PLCδ4a and precede the stop codon. Plasmids 
encoding FKBP-fusions of PLCδ4a and PLCδ4b 
were generated by PCR amplification and 
insertion into the NruI/BamHI sites of the pmRFP-
FKBP-pseudojanin as described above for the 
isolated GBA motifs.  
Yeast Strains and Manipulations- The 
previously described (48) Saccharomyces 
cerevisiae strain CY7967 [MATα GPA1(1-41)-
Gαi3 far1Δ fus1p-HIS3 can1 ste14:trp1:LYS2 
ste3Δ lys2 ura3 leu2 trp1 his3] (kindly provided 
by James Broach, Penn State University) was used 
for all yeast experiments. The main features of this 
strain are that the only pheromone responsive 
GPCR (Ste3) is deleted, the endogenous Gα-
subunit Gpa1 is replaced by a chimeric Gpa1(1-
41)-human Gαi3 (36-354) and the cell cycle arrest-
inducing protein far1 is deleted. In this strain, the 
pheromone response pathway can be upregulated 
by the ectopic expression of activators of human 
Gαi3 and does not results in the cell cycle arrest 
that occurs in the native pheromone response 
(47,48). Plasmid transformations were carried out 
using the lithium acetate method. CY7967 was 
first transformed with a centromeric plasmid (CEN 
TRP) encoding the LacZ gene under the control of 
the FUS1 promoter, which is activated by the 
pheromone response pathway. The PFUS1::LacZ-
expressing strain was transformed with pLIC-
YES2 plasmids (2µm, URA) encoding each one of 
the GBA candidate constructs or Ric-8A described 
in “Plasmid Constructs”. Double transformants 
were selected in synthetic defined (SD)-TRP-URA 
media. Individual colonies were inoculated into 
3ml of SDGalactose-TRP-URA and incubated 
overnight at 30°C to induce the expression of the 
proteins of interest under the control of the 
galactose-inducible promoter of pLIC-YES2. This 
starting culture was used to inoculate 20 ml of 
SDGalactose-TRP-URA at 0.3 OD600. 
Exponentially growing cells (~0.7-0.8 OD600, 4-5 
hours) were pelleted to prepare samples for 
subsequent assays (see “β-galactosidase Activity 
Assay” and “Yeast protein immunoblotting” 
below). 
β-galactosidase Activity Assay- This assay 
was performed as described previously (78) with 
minor modifications. Pellets corresponding to 0.5 
OD600 (in duplicates) were washed once with 
PBS + 0.1% (w:v) BSA and resuspended in 200 µl 
assay buffer (60 mM Na2PO4, 40 mM NaH2PO4, 
10 mM KCl, 1 mM MgCl2, 0.25% (v:v) β-
mercaptoethanol, 0.01% (w:v) SDS, 10% (v:v) 
chloroform) and vortexed. 100 µl were transferred 
to 96-well plates and reactions started by the 
addition of 50 µl of the fluorogenic β-
galactosidase substrate fluorescein di-β-D-
galactopyranoside (FDG, 100 µM final). 
Fluorescence (Ex. 485 ± 10 nm/ Em. 528 ± 10 nm) 
was measured every 2 min for 90 min at 30°C in a 
Biotek H1 synergy plate reader. Enzymatic 
activity was calculated from the slope of 
fluorescence (arbitrary units) versus time (min). At 
least 3 independent experiments were measured 
for each condition and the results normalized (fold 
activation) to the activity in controls (strains 
carrying an empty pLIC-YES2 plasmid). 
Yeast Protein Immunoblotting- This 
assay was performed as described previously 
(78,79) with minor modifications. Briefly, pellets 
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corresponding to 5 OD600 were washed once with 
PBS + 0.1% BSA and resuspended in 150 µl of 
lysis buffer (10 mM Tris-HCl, pH 8.0, 10% (w:v) 
trichloroacetic acid (TCA), 25 mM NH4OAc, 1 
mM EDTA). 100 µl of glass beads were added to 
each tube and vortexed at 4°C for 5 min. Lysates 
were separated from glass beads by poking a hole 
in the bottom of the tubes followed by 
centrifugation onto a new set of tubes. The process 
was repeated after the addition of 50 µl of lysis 
buffer to wash the glass beads. Proteins were 
precipitated by centrifugation (10 min, 20,000 xg) 
and resuspended in 60 µl of solubilization buffer 
(0.1 M Tris-HCl, pH 11.0, 3% SDS). Samples 
were boiled for 5 min, centrifuged (1 min, 20,000 
xg) and 50 µl of the supernatant transferred to new 
tubes containing 12.5 µl of Laemmli sample buffer 
and boiled for 5 min. Proteins (~15-20 µl per lane) 
were separated by SDS-PAGE, blocked in PBS 
supplemented with 5% BSA and analyzed by 
sequential incubation with primary and secondary 
antibodies. Primary antibodies were diluted as 
follows: ppERK (which recognizes yeast ppFus3): 
1:2,500, myc: 1:1,000, and α-tubulin: 1:2,500. 
Secondary antibodies (Goat anti-mouse IRDye 
800 F(ab′)2, Li-Cor Biosciences, and Goat anti-
rabbit Alexa Fluor 680, LifeTechnologies) were 
used at 1:10,000. Images were acquired in an 
Odyssey infrared scanner (Li-Cor), processed 
using ImageJ software (NIH) and assembled for 
presentation using Photoshop and Illustrator 
(Adobe). 
Protein Expression and Purification- All 
His-tagged and GST-tagged proteins were 
expressed in BL21(DE3) E. coli transformed with 
the corresponding plasmids by overnight induction 
at 23 °C with 1 mM isopropyl-β-D-1-thio-
galactopyranoside (IPTG). Protein purification 
was carried out following previously described 
protocols (23,42). Briefly, bacteria pelleted from 1 
L of culture were resuspended in 25 ml of buffer 
[50 mM NaH2PO4, pH 7.4, 300 mM NaCl, 10 mM 
imidazole, 1% (v:v) Triton X-100 supplemented 
with protease inhibitor cocktail (Leupeptin 1 µM, 
Pepstatin 2.5 µM , Aprotinin 0.2 µM, PMSF 1 
mM)]. For rat or human Gαi3, this buffer was 
supplemented with 25 µM GDP and 5 mM MgCl2. 
After sonication (four cycles, with pulses lasting 
20 s/cycle, and with 1 min interval between cycles 
to prevent heating), lysates were centrifuged at 
12,000g for 20 min at 4 °C. The soluble fraction 
(supernatant) of the lysate was used for affinity 
purification on HisPur Cobalt or Glutathione 
Agarose resins (Pierce) and eluted with lysis 
buffer supplemented with 250 mM imidazole or 
with 50 mM Tris-HCl, pH 8, 100 mM NaCl, 30 
mM reduced glutathione, respectively. GST-
tagged proteins were dialyzed overnight at 4 °C 
against PBS. For rat or human His-Gαi3, the 
buffer was exchanged for 20 mM Tris-HCl, pH 
7.4, 20 mM NaCl, 1 mM MgCl2, 1 mM DTT, 10 
μM GDP, 5% (v/v) glycerol using a HiTrap 
Desalting column (GE Healthcare). Validation of 
the quality of the human Gαi3 mutants used in 
Fig. 7B by trypsin protection assays was shown 
previously (29). All protein samples were 
aliquoted and stored at −80 °C. Myristoylated 
Gαi1 was purified from BL21(DE3) E. coli 
bacteria co-expressing NMT as described above 
for His-Gαi3, except that after the cobalt affinity 
purification step the eluate was subjected to ion 
exchange chromatography in a HiTrapQ HP 
column connected to an AKTA FPLC. Bovine 
retinal Gβγ (i.e., Gβ1γ1) was purified as described 
previously. Briefly, holotransducin was purified 
from rod outer segment membranes isolated from 
dark-adapted bovine retina as described previously 
(80). The Gβγ complex was separated from the α-
subunit of transducin on a Hitrap Blue-sepharose 
column (GE healthcare) and further purified using 
anion exchange chromatography using a Hitrap-Q 
column as described earlier (81). Gαi3-Gβγ 
heterotrimers were reconstituted by incubating rat 
His-Gαi3 (20-25 µM) with 2-fold molar excess of 
Gβγ overnight at 4°C in 20 mM Tris-HCl, pH 7.4, 
20 mM NaCl, 1 mM MgCl2, 1 mM DTT, 10 μM 
GDP, 5% (v/v) glycerol. Reconstituted 
heterotrimers were aliquoted and frozen at -80 ºC. 
    
In Vitro Protein Binding Assays- GST 
pulldown assays were carried out as described 
previously (25,42) with minor modifications. For 
Fig. 3, 20-25 μg (~1.5-2 µM final) of GST or 
GST-fused GBA candidates (described in 
“Plasmid Constructs”) were immobilized on 
glutathione agarose beads for 90 min at room 
temperature in PBS. Beads were washed twice 
with PBS, resuspended in 250 µl  of binding 
buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 
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0.4% (v:v) NP-40, 10 mM MgCl2, 5 mM EDTA, 2 
mM DTT, 30 µM GDP) and incubated 4h at 4°C 
with constant tumbling in the presence of 5 µg 
(~0.5 µM final) of rat His-Gαi3. Beads were 
washed four times with 1 ml of wash buffer (4.3 
mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4, 137 mM 
NaCl, 2.7 mM KCl, 0.1% (v/v) Tween-20, 10 mM 
MgCl2, 5 mM EDTA, 1 mM DTT and 30 µM 
GDP) and resin-bound proteins eluted with 
Laemmli sample buffer by incubation at 37°C for 
10 min. The conditions for Fig. 5 were the same 
except that His-Gαi3 was preincubated 3 hours at 
30 ºC in binding buffer supplemented with GDP 
(30 µM), GDP + AlF4- (30 µM AlCl3, 10 mM 
NaF) or GTPγS (30 µM) for PLCD4 or 30 min at 
4º C with GDP or GDP + AlF4- for NOC2L. The 
wash buffer was also supplemented with the same 
nucleotides. For Fig. 7C and Fig. S3 10 µg of the 
indicated GST-fused protein and 1 µg of the G 
protein were used. For Fig. 9B and Fig. S2, 30 µg 
of GST-Gαi3 or GST were used with the lysates of 
~75% of a 10-cm dish of HEK293T cells 
transfected with myc-PLCδ4a,  myc-PLCδ4b or 
other GBA proteins shown in Fig. S2. Proteins 
were separated by SDS-PAGE and transferred to 
PVDF membranes. After blocking with PBS 
supplemented with 5% non-fat milk, membranes 
were analyzed by Ponceau S staining (GST-fused 
proteins) or sequential incubation with primary 
and secondary antibodies. Primary anti-His or 
anti-myc antibodies were used at 1:2,500 or 
1:1,000 dilution, respectively, and secondary 
antibodies (Goat anti-mouse IRDye 800 F(ab′)2, 
Li-Cor Biosciences) at 1:10,000. Immunoblot 
quantification was performed by infrared imaging 
following the manufacturer's protocols using an 
Odyssey imaging system (Li-Cor Biosciences). All 
Odyssey images were processed using the Image J 
software (NIH) and assembled for presentation 
using Photoshop and Illustrator (Adobe).  
Peptide Synthesis- Peptides corresponding 
to the GBA motif of human GIV (residues 1671-
1701, 
KTGSPGSEVVTLQQFLEESNKLTSVQIKSSS), 
human DAPLE (residues 1662-1695, 
SASPSSEMVTLEEFLEESNRSSPTHDTPSCRD
DL), human Calnuc (residues 303-333, 
NVDTNQDRLVTLEEFLASTQRKEFGDTGEG
W), human NUCB2 (residues 304-334, 
EVDTNKDRLVTLEEFLKATEKKEFLEPDSWE
) human PLCD4 (residues 213-243 
ESFSADGQKLTLLEFLDFLQEEQKERDCTSE) 
or human NOC2L (residues 5-35) were 
synthesized using the in situ neutralization 
protocol for Boc-Solid Phase Peptide Synthesis 
(Boc-SPPS) on a p-methylbenzhydrylamine 
(MBHA) resin (Novabiochem, 0.67 mmol/g, 100-
200 mesh). Following chain elongation, 5,6-
carboxyfluorescein was activated with HATU and 
DIEA (4, 4 and 8 equivalents regarding to the 
amount of peptidyl-resin, respectively) and 
coupled to the resin-bound peptides at 65 ºC for 1 
h to yield the carboxyfluorescein-labeled peptides. 
Peptides were cleaved from the resin using a 
solution of hydrofluoric acid (HF) containing 5% 
of anisole for 1 h at 0 ºC. Next, the HF solution 
containing the peptides was removed under 
vacuum and the resulting residues crushed out 
with Et2O and filtered. The collected solids were 
redisolved in a 50% CH3CN/H2O solution 
containing 0.1% of trifluoroacetic acid (TFA), 
frozen down and lyophilized. Crude peptides were 
purified by reverse phase-HPLC using a XBridge 
BEH C18 OBD prep column (130Å, 5 µm, 19 mm 
X 150 mm) at a flow of 20 mL/min using H20 
(0.1% TFA) and CH3CN (0.1%TFA) as eluents. 
The identity and final purity (>97%) of the 
peptides was determined by analytical RP-HPLC 
and mass spectrometry (ESI-TOF). 
Fluorescence Polarization (FP)-based 
Peptide Binding Assays- Fluorescence 
polarization measurements were carried out in 
384-well plates (Black OptiPlate-384F, Perkin 
Elmer). His-Gαi3 proteins (0-32 μM) and 
fluorescently-labeled peptide (0.025 µM) were 
mixed at room temperature for 10 min in a final 
volume of 20 µl of binding buffer (50 mM Tris-
HCl, pH 7.4, 100 mM NaCl, 0.4% (v:v) NP-40, 10 
mM MgCl2, 5 mM EDTA, 2 mM DTT) 
supplemented with 30 µM GDP. Fluorescence 
polarization (Ex. 485 ± 10 nm/ Em. 528 ± 10 nm) 
was measured every 2 min for 30 min at room 
temperature in a Biotek H1 synergy plate reader to 
ensure that the signals were stable in time. 
Fluorescence polarization at different times was 
averaged, normalized to maximal binding and 
fitted to a one site binding model to determine the 
equilibrium dissociation constant (Kd) using Prism 
(GraphPad). 
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Protein Structure Modeling and 
Docking- A model of Gαi3 bound to a portion of 
PLCD4’s GBA motif [aa 219-231] was generated 
by protein-protein docking using ICM version 3.8-
3 (Molsoft LLC., San Diego, CA). Independent 
human Gαi3 and PLCD4 GBA models were first 
generated by homology using the x-ray crystal 
structure of Gαi1 bound to the synthetic GBA 
peptide KB-752 (41) as a starting template (PDB: 
1Y3A; chains B and F for Gαi3 and PLCD4, 
respectively). The side chain positions of the 
separate homology models were energetically 
minimized using a Monte Carlo based method 
after initial construction. Protein-protein docking 
of the PLCD4 peptide to Gαi3 was then 
conducted in silico using a two-stage fast Fourier 
transform method (ICM, Molsoft LLC.). The best 
scoring solution was chosen to represent the 
binding mode. Model images were generated with 
PyMOL Molecular Graphics System (Schrödinger, 
LLC.). 
Steady-state GTPase Assay- This assay 
was performed as described previously (23,25,42). 
Briefly, His-Gαi3 (100 nM) was preincubated with 
different concentrations of GST-PLCD4 GBA  (aa 
213-243) for 15 min at 30˚C in assay buffer [20 
mM Na-HEPES, pH 8, 100 mM NaCl, 1 mM 
EDTA, 25 mM MgCl2, 1 mM DTT, 0.05% (w:v) 
C12E10]. GTPase reactions were initiated at 30˚C 
by adding an equal volume of assay buffer 
containing 1 µM [γ-32P]GTP (~50 c.p.m/ fmol). 
Duplicate aliquots (25 μl) were removed at 15 min 
and reactions stopped with 975 μl of ice-cold 5% 
(w/v) activated charcoal in 20 mM H3PO4, pH 3. 
Samples were then centrifuged for 10 min at 
10,000 xg, and 500 μl of the resultant supernatant 
were scintillation counted to quantify released 
[32P]Pi. Background [32P]Pi detected at 15 min in 
the absence of G protein was subtracted from each 
reaction and data expressed as percentage of the Pi 
produced by His-Gαi3 in the absence of GST-
PLCD4. Background counts were <5% of the 
counts detected in the presence of G proteins. 
Experiments with G protein heterotrimers were 
performed essentially the same way. Briefly, 
reconstituted Gαi3-Gβγ heterotrimers (50 nM/ 100 
nM) were preincubated with His-GIV-CT (2 µM) 
or GST-PLCD4 GBA (6 µM) before starting the 
reactions by the addition of [γ-32P]GTP as 
described above. 
Bioluminescence Resonance Energy 
Transfer (BRET)-based G Protein Activation  
Assays- BRET experiments were conducted as 
described previously (36,82). HEK293T cells 
(ATCC®, CRL-3216) were seeded on 6-well 
plates (~400,000 cells/well) coated with gelatin 
and after one day transfected using the calcium 
phosphate method with plasmids encoding the 
following constructs (DNA amounts in 
parenthesis):  Venus(155-239)-Gβ1 (VC-Gβ1) (0.2 
μg), Venus(1-155)-Gγ2 (VN-Gγ2) (0.2 μg), Gαi3 
(1 μg)  mas-GRK3ct-Nluc (0.2 μg) and Lyn11-
FRB (3 μg) along with FKBP-GBA constructs (0.1 
μg). Approximately 16-24 hours after transfection, 
cells were washed and gently scraped in warm 
PBS, centrifuged (5 min at 550g) and resuspended 
in Tyrode’s solution (140 mM NaCl, 5 mM KCl, 1 
mM MgCl2, 1 mM CaCl2, 0.37 mM NaH2PO4, 24 
mM NaHCO3, 10 mM HEPES pH 7.4, 0.1% 
glucose) at a concentration of ~106 cells/ml. 
25,000 cells were added to a white opaque 96-well 
plate (Opti-Plate, Perkin Elmer) and mixed with 
the nanoluciferase substrate Nano-Glo (Promega, 
final dilution 1:200) for 2 min before measuring 
luminescence. PolarSTAR plate reader (BMG 
Labtech) was used to measure luminescence 
signals at 460 ± 20 nm and 528 ± 10 nm at 28 °C 
and BRET calculated as the ratio between the 
emission intensity at 528 ± 10nm divided by the 
emission intensity at 460 ± 20nm. For the kinetic 
measurements shown in Fig. 8C and Fig. S5, 
BRET was determined every 0.24 s and results 
presented as increase in BRET after subtraction of 
the basal signal measured for 30 s before any 
stimulation [ΔBRET (baseline)]. For the steady-
state BRET measurement shown in Fig. 9C and 
Fig. S7, results were presented as difference in 
BRET compared to the signal in cells not 
expressing PLCD4 [ΔBRET (no PLCD4)]. Protein 
samples from BRET experiments were prepared 
by centrifugation of HEK293T cells and 
resuspension in lysis buffer (20 mM HEPES, pH 
7.2, 5 mM Mg(CH3COO)2, 125 mM 
K(CH3COO), 0.4% Triton X-100, 1 mM DTT, 
and protease inhibitor mixture). After clearing by 
centrifugation at 14,000 × g at 4 °C for 10 min, 
protein concentration was determined by Bradford. 
Samples were supplemented with Laemmli sample 
buffer and boiled for 5 min. Proteins were 
separated by SDS-PAGE and transferred to PVDF 
membranes, which were sequentially incubated 
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with primary and secondary antibodies (goat anti-
rabbit or anti-mouse coupled to Alexa Fluor 680 or 
IRDye 800, 1:10,000). The primary antibodies 
were used at the following dilutions: α-tubulin 
1:2,500, myc 1:1,000, and RFP 1:1,000. Infrared 
imaging of immunoblots was performed according 
to the manufacturer's protocols using an Odyssey 
Infrared Imaging System (Li-Cor Biosciences). All 
Odyssey images were processed using ImageJ 
software (NIH) and assembled for presentation 
using Photoshop and Illustrator (Adobe).  
Intracellular cAMP measurements- This 
assay was performed using the previously 
described BRET-based biosensor NLuc-EPAC-
VV (51,57). HEK293T cells were seeded, 
transfected and harvested as described above 
(“Bioluminescence Resonance Energy Transfer 
(BRET)-based G Protein Activation Assays”) 
except that the plasmids used were (quantities in 
parenthesis):  Nluc-EPAC-VV (0.2 μg), Lyn11-
FRB (3 μg) and FKBP-GBA constructs (0.1 μg). 
A PolarSTAR plate reader (BMG Labtech) was 
used to measure luminescence signals at 460 ± 20 
nm and 528 ± 10 nm at 28 °C every 4 s and BRET 
calculated as the ratio between the emission 
intensity at 528 ± 10nm divided by the emission 
intensity at 460 ± 20nm. Results were presented as 
the inverse of the BRET ratio after subtraction of 
the basal signal measured for 60 s before any 
stimulation (ΔBRET-1). Forskolin (3 µM) was 
added at 60 s and rapamycin (0.5 µM) at 360 s as 
indicated in the figures. Protein sample 
immunoblotting was performed as described in 
“Bioluminescence Resonance Energy Transfer 
(BRET)-based G Protein Activation  Assays”. 
Statistical Analyses- Each experiment was 
performed at least three times. The data shown are 
presented as means with error bars representing 
the S.E.M. or as one representative result of each 
biological replicate (as indicated in the figure 
legends). Statistical significance between various 
conditions was assessed with Student's t test. p < 
0.05 was considered significant. 
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FOOTNOTES 
1The abbreviations used are: GPCR, G protein-coupled receptor; GEF, guanine nucleotide exchange 
factor; GBA, Ga-Binding-and-Activating; GDI: Guanine nucleotide dissociation inhibitor; GAP: GTPase 
activating protein; Gα binding and activating; GIV: Gα Interacting, Vesicle-associated protein; DAPLE: 
Dvl-associating protein with a high frequency of leucines; BRET, Bioluminescence resonance energy 
transfer; AC, adenylyl cyclase; aa, amino acid. 
 
FIGURE LEGENDS 
FIGURE 1. Identification of putative GBA motifs by bioinformatics and peptide array screening. 
(A) Alignment of known GBA sequences of GIV, DAPLE, Calnuc, NUCB2, and GBAS-1 proteins and 
the synthetic peptides KB-752 and GSP. The background was shaded black or grey if the residue was 
identical or similar, respectively, in ≥50% of the sequences. The invariable phenylalanine (F), required for 
G protein binding, is in red. The consensus sequence for the 7 amino acids of the core of the GBA motif 
is shown underneath the alignment (ψ, hydrophobic; x, any). (B) Discovery pipeline for the identification 
and validation of G protein activators with a GBA motif. Putative GBA motifs are identified by 
bioinformatics, tested for G protein binding in a GBA peptide array and the corresponding genes 
evaluated for G protein activation in yeast-based signaling assays. Subsequent steps include validation of 
direct binding of GBA motif-containing proteins to GDP-bound G proteins and assessment of GBA-
dependency for the activation of signaling in yeast. (C) Peptide array screening for binding of GBA motif 
candidates to Gαi3. 25-mer peptides corresponding to each one of the indicated GBA motif candidates 
(full sequences of positive hits shown in Fig. S1) were synthesized and immobilized on slides as one 
peptide per spot. The immobilized peptides were probed in batch with purified His-Gαi3 (Gαi3 +) and 
binding determined after sequential incubation with primary and secondary antibodies coupled to 
fluorescent probes. Control reactions in which the slides were incubated with primary and secondary 
antibodies but without probing with purified His-Gαi3 (Gαi3 -) were performed in parallel. A third slide 
was stained with Coomassie blue (C). The arbitrary units (a.u.) of Gαi3 binding were determined by 
subtracting the signal in the “Gαi3 -“ condition from the signal in the “Gαi3 +“ condition, and 
normalizing to the Coomassie staining signal. Results are the average of 4 experiments (performed with 2 
independent batches of peptide synthesis) and the error bars are the S.E.M. Two peptides corresponding 
to the characterized GBA proteins Calnuc and DAPLE were included as internal controls and the 
previously determined Kd’s for their interaction with Gαi3 are indicated. 
 
FIGURE 2. Assessment of GBA motif-containing gene candidates as G protein activators in 
“humanized” yeast. (A) Schematic of humanized yeast reporter system to determine G protein activation 
by candidate GBA proteins. The pheromone response pathway in Saccharomyces cerevisiae is regulated 
by GPCR-mediated activation of heterotrimeric G proteins, which induces Fus3 phosphorylation and 
transcriptional activation of the FUS1 promoter. A genetically engineered strain lacking endogenous 
pheromone-sensitive GPCRs, expressing human Gαi3 instead of the endogenous Gα Gpa1 and bearing a 
LacZ reporter under the control of the FUS1 promoter was used to determine GPCR-independent G 
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protein activation by exogenously expressed GBA proteins or by Ric-8A (positive control). FUS1 
promoter activity was determined by β-galactosidase activity assays (panel B) and Fus3 activation was 
determined by phosphoERK (ppERK, which recognizes yeast ppFus3) immunoblotting (panel C). (B) 
The β-galactosidase activity of yeast cells expressing the cDNA of the indicated GBA candidates (see 
details for each construct in Fig. S1) was measured as described in “Experimental procedures” and 
normalized relative to the activity in cells expressing an empty vector. Results are the average of six 
independent experiments and the error bars represent the S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 
compared to vector using the Student’s t test. (C) Yeast cells expressing the cDNA of the indicated GBA 
candidates (see details for each construct in Fig. S1) were lysed and proteins analyzed by immunoblotting 
with the indicated antibodies as described in “Experimental procedures”. One representative experiment 
of at least 3 is shown. The red arrowheads indicate the expected position for the full length protein 
corresponding to each construct.  
 
FIGURE 3. PLCD4, NOC2L and K1045 GBA candidates bind directly to Gαi3. Approximately 20 
µg of the indicated purified GST-fused constructs (see details for each construct in Fig. S1) were 
immobilized on glutathione-agarose beads and incubated with 5 µg of purified His-Gαi3 in the presence 
of GDP. Resin-bound proteins were eluted, separated by SDS-PAGE, and analyzed by Ponceau S-
staining and immunoblotting (IB) with the indicated antibodies. Input= 5% of the total amount of His-
Gαi3 added in each binding reaction. One representative experiment of at least three is shown. 
 
FIGURE 4. PLCD4 and NOC2L activate G protein signaling in yeast via their GBA motif. (A) The 
β-galactosidase activity of yeast cells expressing wild-type (WT) or “FA” mutant versions of the 
indicated GBA candidates (PLCD4, left; NOC2L, center; K1045, right) was measured as described in 
“Experimental procedures” and normalized relative to the activity in cells expressing an empty vector. 
Results are the average of six independent experiments and the error bars represent the S.E.M. ***P < 
0.001 compared to the vector control or ###P < 0.001 compared to WT using the Student’s t test. (B) Yeast 
cells expressing the same constructs as in (A) were lysed and proteins analyzed by immunoblotting with 
the indicated antibodies as described in “Experimental procedures”. One representative experiment of at 
least 3 is shown.  
 
FIGURE 5. PLCD4 and NOC2L bind preferentially to GDP-bound Gαi3 over GTP-bound Gαi3. 
Approximately 20 µg of purified GST-PLCD4 (left) or GST-NOC2L (right) (or GST, as negative control) 
immobilized on glutathione-agarose beads were incubated with 5 µg of purified His-Gαi3 preloaded with 
GDP (inactive), GDP + AlF4− (mimics GTP-bound transition state) or GTPγS (non-hydrolyzable GTP 
analog) as indicated. Resin-bound proteins were eluted, separated by SDS-PAGE, and analyzed by 
Ponceau S-staining and immunoblotting (IB) with the indicated antibodies. Input= 5% of the total amount 
of His-Gαi3 added in each binding reaction. One representative experiment of at least three is shown. 
 
FIGURE 6. The GBA motif of PLCD4 binds Gαi3 with high affinity.  (A) Alignment of GBA 31-mer 
peptide sequences of PLCD4, NOC2L, GIV, DAPLE, Calnuc and NUCB2 used in fluorescence 
polarization (FP) assays. The background was shaded black or grey if the residue was identical or similar, 
respectively, in ≥50% of the sequences. The invariable phenylalanine (F), required for G protein binding, 
is in red. A bar diagram of the domains of PLCD4 and NOC2L is presented to show the position of the 
GBA motif in the context of the full proteins. (B) The indicated fluorescently-labeled GBA peptides were 
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incubated with increasing amounts of purified rat His-Gαi3 in the presence of GDP and binding 
determined by FP. Data were normalized to maximal binding (except for NOC2L, for which data is 
presented as increase in millipolarization (mP) units) and fitted to a one-site binding model (solid lines) to 
determine the equilibrium dissociation constant (Kd). Results expressed as average ± S.E.M. of n=3.  
 
FIGURE 7. PLCD4 GBA motif binds to the SwII/α3 helix region of Gαi3 and has GEF activity in 
vitro. (A) Different views of a structure homology model of the complex formed between Gαi3 and the 
GBA motif of PLCD4 with details of the residues within or near the predicted protein-protein interface. 
Left panel, overview of the G protein (blue): GBA motif (orange) complex. PLCD4 GBA motif is 
predicted to bind to the groove formed between the SwII and α3 helix. Middle panels, two representations 
of the same view of the Gαi3:PLCD4 interface. On the view on the right, side chains of amino acids in the 
SwII/α3 helix pocket of Gαi3 mutated in the experiments shown in (B) and displayed in red and the 
PLCD4 GBA motif is omitted for clarity. Right panel, view of conserved hydrophobic amino acid side 
chains in PLCD4 GBA motif predicted to make contact with hydrophobic residues in the SwII/α3 helix 
pocket of Gαi3. (B) The effect of Gαi3 mutations on PLCD4 binding is highly correlated with their effect 
on GIV and DAPLE binding. Left panel, Equilibrium dissociation constants (Kd) for the binding of 
purified human His-Gαi3 mutants to the GBA motif of PLCD4 was determined from FP binding curves 
as described in “Experimental procedures”. Results are expressed as average ± S.E.M. of n=3-5. Fold 
changes in the Kd compared to WT that were larger than 2 or smaller than 0.5 are indicated in red or 
green, respectively. Middle panel, heat map (green to red scale shown on top) of Log2(Kd MUT/Kd WT) for 
each Gαi3 mutant relative to WT comparing PLCD4 GBA binding to previously obtained data (29) for 
GIV or DAPLE GBA binding. Right panels, correlation plots of Log2(Kd MUT/Kd WT) values for PLCD4 
and GIV (top) or PLCD4 and DAPLE (bottom). (C) Mutation of hydrophobic residues in PLCD4 GBA 
motif impairs Gαi3 binding. Approximately 10 µg of purified GST or GST-fused PLCD4 GBA motif (aa 
213-243, WT or bearing the indicating mutations) were immobilized on glutathione-agarose beads and 
incubated with 1 µg of purified rat His-Gαi3 in the presence of GDP. Resin-bound proteins were eluted, 
separated by SDS-PAGE, and analyzed by Ponceau S-staining and immunoblotting (IB) with the 
indicated antibodies. Input= 5% of the total amount of His-Gαi3 added in each binding reaction. One 
representative experiment of at least three is shown. (D) PLCD4 GBA motif increases Gαi3 (left) or 
Gαi3-Gβγ heterotrimer (right) activity in vitro. The steady-state GTPase activity of purified rat His-Gαi3 
or His-Gαi3-Gβγ was determined in the presence of GST-PLCD4 GBA motif WT (black) or FALA 
mutant (red) by measuring the production of [32P]Pi at 15 min as described in “Experimental procedures”. 
The effect of His-GIV-CT (aa 1660-1870, containing the GBA motif) WT (black) or F1685A mutant 
(red) on the activity of the Gαi3-Gβγ heterotrimer was also tested. Results are the average ± S.E.M. of 
n=3. **P<0.01 using the Student’s t test. 
 
FIGURE 8. PLCD4 GBA motif activates G protein signaling in cells. (A) Left, Translocation of GBA 
sequences to membranes is controlled by CID using the FKBP-rapamycin-FRB system. FKBP-fused 
GBA is recruited to membranes upon rapamycin-induced binding of FKBP to the FRB domain that is 
fused to a membrane-targeting sequence (Lyn11). Right, G protein activation is determined by BRET. 
Dissociation of Gαi3:Gβγ trimers upon G protein activation leads to the release of Venus-tagged Gβγ (V-
Gβγ), which binds to the C-terminal domain of GRK3 fused to nanoluciferase (GRK3ct-Nluc) and causes 
an increase in BRET signal. (B) Immunoblot of FKBP-fused GBA motifs (WT or FA mutants) of human 
GIV (aa 1671-1701), DAPLE (aa 1661-1691), Calnuc (aa 303-333), NUCB2 (aa 304-334) or PLCD4 (aa 
213-243) expressed in HEK293T cells used for the experiments shown in (C). (C) Rapamycin-induced 
translocation of FKBP-fused WT GBA motifs (black) leads to G protein activation as determined by 
BRET, and FA mutations (red) abolish or diminish this response. HEK293T cells expressing all the 
required assay components and transfected with equal amounts of plasmids encoding the FKBP-GBA 
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fusions (0.1 µg per well) were treated with rapamycin (0.5 μM) at the indicated time point (arrow). 
Results are the average ± S.E.M. (shown only at 5-s intervals for clarity) of n=4 expressed as increase in 
BRET after rapamycin stimulation (ΔBRET, baseline corrected by subtraction of the BRET values before 
stimulation). Lower right panel, scatter plot of ΔBRET 90 seconds after rapamycin addition for the 
indicated FKBP-GBA constructs. *P<0.05, **P<0.01, ***P<0.001 compared to the respective WT using 
the Student’s t test. The graph and immunoblot bands for FKBP-GBA PLCD4 have been reused in Fig. 
S4 for comparison with other results. (D) Left, Translocation of GBA sequences to membranes is 
controlled by CID using the FKBP-rapamycin-FRB system and in (A). Right, cAMP levels are measured 
by BRET using the Nluc-EPAC-VV sensor. Gαi3-GTP negatively regulates adenylyl cyclase (AC), 
thereby diminishing cAMP levels induced upon forskolin-mediated activation of AC. (E) Immunoblot of 
FKBP-fused GBA motifs  of human GIV or PLCD4 expressed in HEK293T cells used for the 
experiments shown in (F). (F) Rapamycin-induced translocation of FKBP-GBA GIV or FKBP-GBA 
PLCD4 inhibits forskolin-induced cAMP levels. HEK293T cells expressing the cAMP sensor Nluc-
EPAC-VV, Lyn11-FRB and the indicated FKBP-fused GBA constructs were treated at the indicated 
times (arrows) with forskolin alone (3 µM, black), forskolin followed by rapamycin (0.5 µM, red) or no 
compound (grey). One representative experiment is shown on the left graphs and a scatter plot of 
rapamycin-induced inhibition of forskolin-stimulated cAMP levels from n=4 is shown on the right. The 
scatter plot includes results of analogous experiments with cells expressing the α2A adrenergic receptor 
and stimulated with brimonidine (5 µM) instead of rapamycin for comparison.  **P<0.01, ***P<0.001 
compared to the control cells (-) using the Student’s t test.  
 
FIGURE 9. PLCδ4b binds Gαi3 more efficiently than PLCδ4a and activates G proteins in cells. (A)  
Bar diagrams of human PLCδ4 isoforms and constructs. PLCδ4a contains (from N to C terminus) a PH 
domain, two EF-hands, an EF-hand-like domain that overlaps with the GBA motif, a catalytic TIM barrel 
(with X- and Y-boxes) and a C2 domain. PLCδ4b and PLCδ4 (1-260) are truncated before the catalytic 
TIM barrel. Inset, partial sequence alignment of PLCδ4a, PLCδ4b and PLCδ4 (1-260). The C-terminal 
sequence of PLCδ4b differs from PLCδ4a in the 14 aa preceding its stop codon, and the PLCδ4 (1-260) 
construct used in previous experiments (Figs. 2 to 5) is very similar to PLCδ4b. (B) Gαi3 binding of two 
PLCδ4 isoforms. Approximately 30 µg of purified GST-Gαi3 or GST immobilized on glutathione-
agarose beads were incubated with lysates of HEK293T cells expressing either myc-PLCδ4a (left) or 
myc-PLCδ4b (right) in the presence of GDP. Resin-bound proteins were eluted, separated by SDS-
PAGE, and analyzed by Ponceau S-staining and immunoblotting (IB) with the indicated antibodies. Three 
different capture intensities (low, medium, and high) are shown for the myc IB. Input= 2.5% of the total 
amount of lysate added in each binding reaction. One representative experiment of at least three is shown. 
(C) PLCδ4b, but not PLCδ4a, activates G protein signaling in cells via its GBA motif. HEK293T cells 
were transfected with the indicated amounts of plasmids for the expression of myc-PLCδ4a (WT) or myc-
PLCδ4b (WT or FALA mutants) and all the required components of the BRET-based G protein activity 
assay described in Fig. 8A (Gαi3, V-Gβγ and GRK3ct-Nluc). Results from n=5 are presented as the 
increase in BRET (ΔBRET) compared to cells not expressing PLCδ4 in a box-and-whisker plot (median 
with boxes of 25-75%ile and error bars indicating the range. Cross marks indicate the average). An 
immunoblot (IB) of a representative experiment is shown below the graph.  **P<0.01 compared to the 
respective WT using the Student’s t test. 
 
FIGURE 10. PLCδ4b inhibits forskolin-induced cAMP formation. (A, B, C) BRET-based cAMP 
measurements upon rapamycin-mediated recruitment of FKBP-PLCδ4a or FKBP-PLCδ4b were 
performed exactly as described in Fig. 8D. HEK293T cells expressing the cAMP sensor Nluc-EPAC-VV, 
Lyn11-FRB and the indicated FKBP-PLCδ4 constructs (0.25 µg DNA per well) were treated at the 
indicated times (arrows) with forskolin alone (3 µM, black), forskolin followed by rapamycin (0.5 µM, 
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red) or no compound (grey). One representative experiment is shown in (A) and a scatter plot of 
rapamycin-induced inhibition of forskolin-stimulated cAMP levels from n=3 is shown in (B). **P<0.01 
compared to the control cells (-) using the Student’s t test. An immunoblot of cell lysates from one 
representative experiment is shown in (C). (D) BRET-based cAMP measurements upon rapamycin-
mediated recruitment of FKBP-PLCδ4a or FKBP-PLCδ4b were performed and quantified as described in 
(A, B, C) in the presence of the PLC inhibitor U73122 (+) (10 µM, 60 min preincubation) or DMSO (-). 
Results are the average ± S.E.M. of n=4. **P<0.01, ns= not significant compared to control cells 
pretreated with DMSO (-) using the Student’s t test.   
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FIGURE 1. Identification of putative GBA motifs by bioinformatics and peptide array screening. (A) Alignment of known GBA sequences of GIV, 
DAPLE, Calnuc, NUCB2, and GBAS-1 proteins and the synthetic peptides KB-752 and GSP. The background was shaded black or grey if the residue was 
identical or similar, respectively, in ≥50% of the sequences. The invariable phenylalanine (F), required for G protein binding, is in red. The consensus sequence 
for the 7 amino acids of the core of the GBA motif is shown underneath the alignment (ψ, hydrophobic; x, any). (B) Discovery pipeline for the identification and 
validation of G protein activators with a GBA motif. Putative GBA motifs are identified by bioinformatics, tested for G protein binding in a GBA peptide array 
and the corresponding genes evaluated for G protein activation in yeast-based signaling assays. Subsequent steps include validation of direct binding of GBA 
motif-containing proteins to GDP-bound G proteins and assessment of GBA-dependency for the activation of signaling in yeast. (C) Peptide array screening for 
binding of GBA motif candidates to Gαi3. 25-mer peptides corresponding to each one of the indicated GBA motif candidates (full sequences of positive hits 
shown in Fig. S1) were synthesized and immobilized on slides as one peptide per spot. The immobilized peptides were probed in batch with purified His-Gαi3 
(Gαi3 +) and binding determined after sequential incubation with primary and secondary antibodies coupled to fluorescent probes. Control reactions in which the 
slides were incubated with primary and secondary antibodies but without probing with purified His-Gαi3 (Gαi3 -) were performed in parallel. A third slide was 
stained with Coomassie blue (C). The arbitrary units (a.u.) of Gαi3 binding were determined by subtracting the signal in the “Gαi3 -“ condition from the signal in 
the “Gαi3 +“ condition, and normalizing to the Coomassie staining signal. Results are the average of 4 experiments (performed with 2 independent batches of 
peptide synthesis) and the error bars are the S.E.M. Two peptides corresponding to the characterized GBA proteins Calnuc and DAPLE were included as internal 
controls and the previously determined Kd’s for their interaction with Gαi3 are indicated. 
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FIGURE 2. Assessment of GBA motif-containing gene candidates as G protein activators in “humanized” yeast. (A) Schematic of humanized yeast 
reporter system to determine G protein activation by candidate GBA proteins. The pheromone response pathway in Saccharomyces cerevisiae is regulated by 
GPCR-mediated activation of heterotrimeric G proteins, which induces Fus3 phosphorylation and transcriptional activation of the FUS1 promoter. A genetically 
engineered strain lacking endogenous pheromone-sensitive GPCRs, expressing human Gαi3 instead of the endogenous Gα Gpa1 and bearing a LacZ reporter 
under the control of the FUS1 promoter was used to determine GPCR-independent G protein activation by exogenously expressed GBA proteins or by Ric-8A 
(positive control). FUS1 promoter activity was determined by β-galactosidase activity assays (panel B) and Fus3 activation was determined by phosphoERK 
(ppERK, which recognizes yeast ppFus3) immunoblotting (panel C). (B) The β-galactosidase activity of yeast cells expressing the cDNA of the indicated GBA 
candidates (see details for each construct in Fig. S1) was measured as described in “Experimental procedures” and normalized relative to the activity in cells 
expressing an empty vector. Results are the average of six independent experiments and the error bars represent the S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 
compared to vector using the Student’s t test. (C) Yeast cells expressing the cDNA of the indicated GBA candidates (see details for each construct in Fig. S1) 
were lysed and proteins analyzed by immunoblotting with the indicated antibodies as described in “Experimental procedures”. One representative experiment of 
at least 3 is shown. The red arrowheads indicate the expected position for the full length protein corresponding to each construct.  
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FIGURE 3. PLCD4, NOC2L and K1045 GBA candidates bind directly to Gαi3. Approximately 20 µg of the indicated purified GST-fused 
constructs (see details for each construct in Fig. S1) were immobilized on glutathione-agarose beads and incubated with 5 µg of purified His-Gαi3 
in the presence of GDP. Resin-bound proteins were eluted, separated by SDS-PAGE, and analyzed by Ponceau S-staining and immunoblotting 
(IB) with the indicated antibodies. Input= 5% of the total amount of His-Gαi3 added in each binding reaction. One representative experiment of at 
least three is shown. 
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FIGURE 4. PLCD4 and NOC2L activate G protein signaling in yeast via their GBA motif. (A) The β-galactosidase activity of yeast cells 
expressing wild-type (WT) or “FA” mutant versions of the indicated GBA candidates (PLCD4, left; NOC2L, center; K1045, right) was measured 
as described in “Experimental procedures” and normalized relative to the activity in cells expressing an empty vector. Results are the average of 
six independent experiments and the error bars represent the S.E.M. ***P < 0.001 compared to the vector control or ###P < 0.001 compared to WT 
using the Student’s t test. (B) Yeast cells expressing the same constructs as in (A) were lysed and proteins analyzed by immunoblotting with the 
indicated antibodies as described in “Experimental procedures”. One representative experiment of at least 3 is shown.  
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FIGURE 5. PLCD4 and NOC2L bind preferentially to GDP-bound Gαi3 over GTP-bound Gαi3. Approximately 20 µg of purified GST-
PLCD4 (left) or GST-NOC2L (right) (or GST, as negative control) immobilized on glutathione-agarose beads were incubated with 5 µg of 
purified His-Gαi3 preloaded with GDP (inactive), GDP + AlF4− (mimics GTP-bound transition state) or GTPγS (non-hydrolyzable GTP analog) as 
indicated. Resin-bound proteins were eluted, separated by SDS-PAGE, and analyzed by Ponceau S-staining and immunoblotting (IB) with the 
indicated antibodies. Input= 5% of the total amount of His-Gαi3 added in each binding reaction. One representative experiment of at least three is 
shown. 
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FIGURE 6. The GBA motif of PLCD4 binds Gαi3 with high affinity.  (A) Alignment of GBA 31-mer peptide sequences of PLCD4, NOC2L, 
GIV, DAPLE, Calnuc and NUCB2 used in fluorescence polarization (FP) assays. The background was shaded black or grey if the residue was 
identical or similar, respectively, in ≥50% of the sequences. The invariable phenylalanine (F), required for G protein binding, is in red. A bar 
diagram of the domains of PLCD4 and NOC2L is presented to show the position of the GBA motif in the context of the full proteins. (B) The 
indicated fluorescently-labeled GBA peptides were incubated with increasing amounts of purified rat His-Gαi3 in the presence of GDP and 
binding determined by FP. Data were normalized to maximal binding (except for NOC2L, for which data is presented as increase in 
millipolarization (mP) units) and fitted to a one-site binding model (solid lines) to determine the equilibrium dissociation constant (Kd). Results 
expressed as average ± S.E.M. of n=3.  
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FIGURE 7. PLCD4 GBA motif binds to the SwII/α3 helix region of Gαi3 and has GEF activity in vitro. (A) Different views of a structure 
homology model of the complex formed between Gαi3 and the GBA motif of PLCD4 with details of the residues within or near the predicted 
protein-protein interface. Left panel, overview of the G protein (blue): GBA motif (orange) complex. PLCD4 GBA motif is predicted to bind to the 
groove formed between the SwII and α3 helix. Middle panels, two representations of the same view of the Gαi3:PLCD4 interface. On the view on 
the right, side chains of amino acids in the SwII/α3 helix pocket of Gαi3 mutated in the experiments shown in (B) and displayed in red and the 
PLCD4 GBA motif is omitted for clarity. Right panel, view of conserved hydrophobic amino acid side chains in PLCD4 GBA motif predicted to 
make contact with hydrophobic residues in the SwII/α3 helix pocket of Gαi3. (B) The effect of Gαi3 mutations on PLCD4 binding is highly 
correlated with their effect on GIV and DAPLE binding. Left panel, Equilibrium dissociation constants (Kd) for the binding of purified human His-
Gαi3 mutants to the GBA motif of PLCD4 was determined from FP binding curves as described in “Experimental procedures”. Results are 
expressed as average ± S.E.M. of n=3-5. Fold changes in the Kd compared to WT that were larger than 2 or smaller than 0.5 are indicated in red or 
green, respectively. Middle panel, heat map (green to red scale shown on top) of Log2(Kd MUT/Kd WT) for each Gαi3 mutant relative to WT 
comparing PLCD4 GBA binding to previously obtained data (29) for GIV or DAPLE GBA binding. Right panels, correlation plots of Log2(Kd 
MUT/Kd WT) values for PLCD4 and GIV (top) or PLCD4 and DAPLE (bottom). (C) Mutation of hydrophobic residues in PLCD4 GBA motif 
impairs Gαi3 binding. Approximately 10 µg of purified GST or GST-fused PLCD4 GBA motif (aa 213-243, WT or bearing the indicating 
mutations) were immobilized on glutathione-agarose beads and incubated with 1 µg of purified rat His-Gαi3 in the presence of GDP. Resin-bound 
proteins were eluted, separated by SDS-PAGE, and analyzed by Ponceau S-staining and immunoblotting (IB) with the indicated antibodies. Input= 
5% of the total amount of His-Gαi3 added in each binding reaction. One representative experiment of at least three is shown. (D) PLCD4 GBA 
motif increases Gαi3 (left) or Gαi3-Gβγ heterotrimer (right) activity in vitro. The steady-state GTPase activity of purified rat His-Gαi3 or His-
Gαi3-Gβγ was determined in the presence of GST-PLCD4 GBA motif WT (black) or FALA mutant (red) by measuring the production of [32P]Pi 
at 15 min as described in “Experimental procedures”. The effect of His-GIV-CT (aa 1660-1870, containing the GBA motif) WT (black) or 
F1685A mutant (red) on the activity of the Gαi3-Gβγ heterotrimer was also tested. Results are the average ± S.E.M. of n=3. **P<0.01 using the 
Student’s t test. 
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FIGURE 8. PLCD4 GBA motif activates G protein signaling in cells. (A) Left, Translocation of GBA sequences to membranes is controlled by 
CID using the FKBP-rapamycin-FRB system. FKBP-fused GBA is recruited to membranes upon rapamycin-induced binding of FKBP to the FRB 
domain that is fused to a membrane-targeting sequence (Lyn11). Right, G protein activation is determined by BRET. Dissociation of Gαi3:Gβγ 
trimers upon G protein activation leads to the release of Venus-tagged Gβγ (V-Gβγ), which binds to the C-terminal domain of GRK3 fused to 
nanoluciferase (GRK3ct-Nluc) and causes an increase in BRET signal. (B) Immunoblot of FKBP-fused GBA motifs (WT or FA mutants) of 
human GIV (aa 1671-1701), DAPLE (aa 1661-1691), Calnuc (aa 303-333), NUCB2 (aa 304-334) or PLCD4 (aa 213-243) expressed in HEK293T 
cells used for the experiments shown in (C). (C) Rapamycin-induced translocation of FKBP-fused WT GBA motifs (black) leads to G protein 
activation as determined by BRET, and FA mutations (red) abolish or diminish this response. HEK293T cells expressing all the required assay 
components and transfected with equal amounts of plasmids encoding the FKBP-GBA fusions (0.1 µg per well) were treated with rapamycin (0.5 
μM) at the indicated time point (arrow). Results are the average ± S.E.M. (shown only at 5-s intervals for clarity) of n=4 expressed as increase in 
BRET after rapamycin stimulation (ΔBRET, baseline corrected by subtraction of the BRET values before stimulation). Lower right panel, scatter 
plot of ΔBRET 90 seconds after rapamycin addition for the indicated FKBP-GBA constructs. *P<0.05, **P<0.01, ***P<0.001 compared to the 
respective WT using the Student’s t test. The graph and immunoblot bands for FKBP-GBA PLCD4 have been reused in Fig. S4 for comparison 
with other results. (D) Left, Translocation of GBA sequences to membranes is controlled by CID using the FKBP-rapamycin-FRB system and in 
(A). Right, cAMP levels are measured by BRET using the Nluc-EPAC-VV sensor. Gαi3-GTP negatively regulates adenylyl cyclase (AC), thereby 
diminishing cAMP levels induced upon forskolin-mediated activation of AC. (E) Immunoblot of FKBP-fused GBA motifs  of human GIV or 
PLCD4 expressed in HEK293T cells used for the experiments shown in (F). (F) Rapamycin-induced translocation of FKBP-GBA GIV or FKBP-
GBA PLCD4 inhibits forskolin-induced cAMP levels. HEK293T cells expressing the cAMP sensor Nluc-EPAC-VV, Lyn11-FRB and the 
indicated FKBP-fused GBA constructs were treated at the indicated times (arrows) with forskolin alone (3 µM, black), forskolin followed by 
rapamycin (0.5 µM, red) or no compound (grey). One representative experiment is shown on the left graphs and a scatter plot of rapamycin-
induced inhibition of forskolin-stimulated cAMP levels from n=4 is shown on the right. The scatter plot includes results of analogous experiments 
with cells expressing the α2A adrenergic receptor and stimulated with brimonidine (5 µM) instead of rapamycin for comparison.  **P<0.01, 
***P<0.001 compared to the control cells (-) using the Student’s t test.  
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FIGURE 9. PLCδ4b binds Gαi3 more efficiently than PLCδ4a and activates G proteins in cells. (A)  Bar diagrams of human PLCδ4 
isoforms and constructs. PLCδ4a contains (from N to C terminus) a PH domain, two EF-hands, an EF-hand-like domain that overlaps with the 
GBA motif, a catalytic TIM barrel (with X- and Y-boxes) and a C2 domain. PLCδ4b and PLCδ4 (1-260) are truncated before the catalytic TIM 
barrel. Inset, partial sequence alignment of PLCδ4a, PLCδ4b and PLCδ4 (1-260). The C-terminal sequence of PLCδ4b differs from PLCδ4a in the 
14 aa preceding its stop codon, and the PLCδ4 (1-260) construct used in previous experiments (Figs. 2 to 5) is very similar to PLCδ4b. (B) Gαi3 
binding of two PLCδ4 isoforms. Approximately 30 µg of purified GST-Gαi3 or GST immobilized on glutathione-agarose beads were incubated 
with lysates of HEK293T cells expressing either myc-PLCδ4a (left) or myc-PLCδ4b (right) in the presence of GDP. Resin-bound proteins were 
eluted, separated by SDS-PAGE, and analyzed by Ponceau S-staining and immunoblotting (IB) with the indicated antibodies. Three different 
capture intensities (low, medium, and high) are shown for the myc IB. Input= 2.5% of the total amount of lysate added in each binding reaction. 
One representative experiment of at least three is shown. (C) PLCδ4b, but not PLCδ4a, activates G protein signaling in cells via its GBA motif. 
HEK293T cells were transfected with the indicated amounts of plasmids for the expression of myc-PLCδ4a (WT) or myc-PLCδ4b (WT or FALA 
mutants) and all the required components of the BRET-based G protein activity assay described in Fig. 8A (Gαi3, V-Gβγ and GRK3ct-Nluc). 
Results from n=5 are presented as the increase in BRET (ΔBRET) compared to cells not expressing PLCδ4 in a box-and-whisker plot (median 
with boxes of 25-75%ile and error bars indicating the range. Cross marks indicate the average). An immunoblot (IB) of a representative 
experiment is shown below the graph.  **P<0.01 compared to the respective WT using the Student’s t test. 
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FIGURE 10. PLCδ4b inhibits forskolin-induced cAMP formation. (A, B, C) BRET-based cAMP measurements upon rapamycin-mediated 
recruitment of FKBP-PLCδ4a or FKBP-PLCδ4b were performed exactly as described in Fig. 8D. HEK293T cells expressing the cAMP sensor 
Nluc-EPAC-VV, Lyn11-FRB and the indicated FKBP-PLCδ4 constructs (0.25 µg DNA per well) were treated at the indicated times (arrows) with 
forskolin alone (3 µM, black), forskolin followed by rapamycin (0.5 µM, red) or no compound (grey). One representative experiment is shown in 
(A) and a scatter plot of rapamycin-induced inhibition of forskolin-stimulated cAMP levels from n=3 is shown in (B). **P<0.01, ***P<0.001 
compared to the control cells (-) using the Student’s t test. An immunoblot of cell lysates from one representative experiment is shown in (C). (D) 
BRET-based cAMP measurements upon rapamycin-mediated recruitment of FKBP-PLCδ4a or FKBP-PLCδ4b were performed and quantified as 
described in (A, B, C) in the presence of the PLC inhibitor U73122 (+) (10 µM, 60 min preincubation) or DMSO (-). Results are the average ± 
S.E.M. of n=4. **P<0.01, ns= not significant compared to control cells pretreated with DMSO (-) using the Student’s t test.   
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